Evolent Health (EVH) 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Evolent Health, Inc.
Entity Central Index Key	1,628,908
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Class A
Entity Common Stock, Shares Outstanding (in shares)		78,341,481
Class B
Entity Common Stock, Shares Outstanding (in shares)		3,885,947

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 221,837	$ 238,433
Restricted cash and restricted investments	42,328	62,398
Accounts receivable, net (amounts related to affiliates: 2018 - $7,774; 2017 - $3,358)	60,054	48,947
Prepaid expenses and other current assets (amounts related to affiliates: 2018 - $48; 2017 - $25)	14,667	8,404
Notes receivable	6,000	20,000
Contract assets	3,705	0
Total current assets	348,591	378,182
Restricted cash and restricted investments	3,394	3,287
Investments in and advances to equity method investees	5,672	1,531
Property and equipment, net	68,692	50,922
Prepaid expenses and other noncurrent assets (amounts related to affiliates: 2018 - $2,500; 2017 - $0)	15,181	9,328
Contract assets	1,000	0
Contract cost assets	14,252	0
Intangible assets, net	230,806	241,261
Goodwill	635,088	628,186
Total assets	1,322,676	1,312,697
Current liabilities:
Accounts payable (amounts related to affiliates: 2018 - $1,425; 2017 - $10,284)	30,535	42,930
Accrued liabilities (amounts related to affiliates: 2018 - $4,812; 2017 - $719)	47,189	29,572
Accrued compensation and employee benefits	28,989	35,390
Deferred revenue	22,360	24,807
Claims reserves	10,338	0
Total current liabilities	139,411	132,699
Long-term debt, net of discount	122,082	121,394
Other long-term liabilities	10,885	9,861
Deferred tax liabilities, net	1,725	2,437
Total liabilities	274,103	266,391
Commitments and Contingencies (See Note 9)
Shareholders' Equity (Deficit)
Additional paid-in capital	971,341	924,153
Accumulated other comprehensive income (loss)	(264)	0
Retained earnings (accumulated deficit)	66,696	85,952
Total shareholders' equity (deficit) attributable to Evolent Health, Inc.	1,038,565	1,010,879
Non-controlling interests	10,008	35,427
Total shareholders' equity (deficit)	1,048,573	1,046,306
Total liabilities and shareholders' equity (deficit)	1,322,676	1,312,697
Class A
Shareholders' Equity (Deficit)
Common stock	784	747
Class B
Shareholders' Equity (Deficit)
Common stock	$ 8	$ 27

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, related parties	$ 7,774	$ 3,358
Prepaid expenses and other current assets, related parties	48	25
Prepaid expenses and other noncurrent assets, related parties	2,500	0
Accounts payable, related parties	1,425	10,284
Accrued liabilities, related parties	$ 4,812	$ 719
Class A
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	78,392,052	74,723,597
Common stock, outstanding (in shares)	78,392,052	74,723,597
Class B
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	100,000,000	100,000,000
Common stock, issued (in shares)	765,646	2,653,544
Common stock, outstanding (in shares)	765,646	2,653,544

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue
Revenues		$ 149,947	$ 107,912	$ 433,959	$ 321,221
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)	[1]	73,967	68,281	214,945	203,804
Claims expenses		16,992	0	52,169	0
Selling, general and administrative expenses	[1]	59,566	45,834	172,495	150,474
Depreciation and amortization expenses		10,352	7,717	29,882	21,236
Change in fair value of contingent consideration and indemnification asset		100	100	(1,404)	300
Total operating expenses		160,977	121,932	468,087	375,814
Operating income (loss)		(11,030)	(14,020)	(34,128)	(54,593)
Interest income		968	411	2,918	813
Interest expense		(853)	(880)	(2,561)	(2,781)
Income (loss) from equity method investees		(1,381)	(369)	(2,787)	(1,446)
Other income (expense), net		(124)	15	(64)	21
Income (loss) before income taxes and non-controlling interests		(12,420)	(14,843)	(36,622)	(57,986)
Provision (benefit) for income taxes		135	(1,714)	29	(2,009)
Net income (loss)		(12,555)	(13,129)	(36,651)	(55,977)
Net income (loss) attributable to non-controlling interests		(126)	(541)	(680)	(8,471)
Net income (loss) attributable to Evolent Health, Inc.		(12,429)	(12,588)	(35,971)	(47,506)
Earnings (Loss) Available for Common Shareholders
Basic		(12,429)	(12,588)	(35,971)	(47,506)
Diluted		$ (12,429)	$ (12,588)	$ (35,971)	$ (47,506)
Earnings (Loss) per Common Share
Basic (in dollars per share)		$ (0.16)	$ (0.18)	$ (0.47)	$ (0.78)
Diluted (in dollars per share)		$ (0.16)	$ (0.18)	$ (0.47)	$ (0.78)
Weighted-Average Common Shares Outstanding
Basic (in shares)		77,999	70,328	76,871	60,867
Diluted (in shares)		77,999	70,328	76,871	60,867
Comprehensive income (loss)
Net income (loss)		$ (12,555)	$ (13,129)	$ (36,651)	$ (55,977)
Other comprehensive income (loss), net of taxes, related to:
Foreign currency translation adjustment		(116)	0	(264)	0
Total comprehensive income (loss)		(12,671)	(13,129)	(36,915)	(55,977)
Total comprehensive income (loss) attributable to non-controlling interests		(126)	(541)	(680)	(8,471)
Total comprehensive income (loss) attributable to Evolent Health, Inc.		(12,545)	(12,588)	(36,235)	(47,506)
Transformation services
Revenue
Revenues	[1]	9,230	8,204	23,950	23,799
Platform and operations services
Revenue
Revenues	[1]	118,094	99,708	341,258	297,422
Premiums
Revenue
Revenues		$ 22,623	$ 0	$ 68,751	$ 0
[1]	See Note 16 for amounts related to affiliates included in these line items.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Operating Activities
Net income (loss)	$ (36,651)	$ (55,977)
Adjustments to reconcile net income (loss) to net cash and restricted cash provided by (used in) operating activities:
(Income) loss from equity method investees	2,787	1,446
Change in fair value of contingent consideration and indemnification asset	(1,404)	300
Depreciation and amortization expenses	29,882	21,236
Amortization of deferred financing costs	688	685
Stock-based compensation expense	12,560	16,172
Deferred tax provision (benefit)	34	(2,668)
Amortization of contract cost assets	1,900	0
Other	(111)	88
Changes in assets and liabilities, net of acquisitions:
Accounts receivables, net	(11,241)	(5,075)
Prepaid expenses and other current and noncurrent assets	(15,393)	(5,125)
Contract assets	240	0
Contract cost assets	(4,568)	0
Accounts payable	6,451	10,591
Accrued liabilities	13,946	(11,075)
Accrued compensation and employee benefits	(7,059)	(7,707)
Deferred revenue	828	4,835
Claims reserves	10,338	0
Other long-term liabilities	1,090	(1,719)
Net cash and restricted cash provided by (used in) operating activities	4,317	(33,993)
Cash Flows from Investing Activities
Cash paid for asset acquisitions or business combinations	(11,552)	(3,694)
Principal repayment for implementation funding loan	14,000	0
Amount received from escrow in asset acquisition	500	0
Maturities and sales of investments	0	44,210
Investments in and advances to equity method investees	(6,807)	0
Purchases of property and equipment	(29,117)	(21,349)
Purchases and maturities of restricted investments	8,043	(3,200)
Net cash and restricted cash provided by (used in) investing activities	(24,933)	15,967
Cash Flows from Financing Activities
Change in restricted cash held on behalf of partners for claims processing	(17,344)	(25,648)
Proceeds from issuance of common stock, net of stock issuance costs	0	166,947
Proceeds from stock option exercises	10,588	3,802
Taxes withheld and paid for vesting of restricted stock units	(1,179)	(1,179)
Net cash and restricted cash provided by (used in) financing activities	(7,935)	143,922
Effect of exchange rate on cash and cash equivalents and restricted cash	35	0
Net increase (decrease) in cash and cash equivalents and restricted cash	(28,516)	125,896
Cash and cash equivalents and restricted cash as of beginning-of-period	295,363	170,029
Cash and cash equivalents and restricted cash as of end-of-period	$ 266,847	$ 295,925

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Class A	Common StockClass A	Common StockClass B	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2016			52,587	15,347
Beginning balance, amount at Dec. 31, 2016	$ 912,114		$ 506	$ 153	$ 555,250	$ 0	$ 146,617	$ 209,588
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	20,437				20,437
Exercise of stock options (in shares)			788
Exercise of stock options	4,082		$ 28		4,054
Restricted stock units vested, net of shares withheld for taxes (in shares)			149
Restricted stock units vested, net of shares withheld for taxes	(1,272)		$ 2		(1,274)
Shares released from Valence Health escrow (in shares)			(310)
Shares released from Valence Health escrow	908		$ (3)		911
Exchange of Class B common stock (in shares)			12,693	(12,693)
Exchange of Class B common stock	0		$ 126	$ (126)	168,883			(168,883)
Tax impact of share issuances	12,857				12,857
Issuance of Class A common stock during August 2017 Primary (in shares)		20,100	8,816
Issuance of Class A common stock during August 2017 Primary	166,947		$ 88		166,859
Reclassification of non-controlling interests	0				(3,824)			3,824
Net income (loss)	(69,767)						(60,665)	(9,102)
Ending balance (in shares) at Dec. 31, 2017			74,723	2,654
Ending balance, amount at Dec. 31, 2017	1,046,306		$ 747	$ 27	924,153	0	85,952	35,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASC 606	17,309						16,715	594
Stock-based compensation expense	12,560				12,560
Exercise of stock options (in shares)			1,574
Exercise of stock options	10,588		$ 16		10,572
Restricted stock units vested, net of shares withheld for taxes (in shares)			207
Restricted stock units vested, net of shares withheld for taxes	(1,179)		$ 2		(1,181)
Exchange of Class B common stock (in shares)			1,888	(1,888)
Exchange of Class B common stock	0		$ 19	$ (19)	25,334			(25,334)
Tax impact of Class B Exchanges	908				908
Settlement of indemnification asset	(1,004)				(1,004)
Foreign Currency Translation Adjustment	(264)					(264)
Reclassification of non-controlling interests	0				(1)			1
Net income (loss)	(36,651)						(35,971)	(680)
Ending balance (in shares) at Sep. 30, 2018			78,392	766
Ending balance, amount at Sep. 30, 2018	$ 1,048,573		$ 784	$ 8	$ 971,341	$ (264)	$ 66,696	$ 10,008

Organization

Organization	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware, and is a managed services firm that supports leading health systems and physician organizations in their migration toward value-based care and population health management. The Company operates through two segments. The Company’s services segment (“Services”) provides our customers, who we refer to as partners, with a population management platform, integrated data and analytics capabilities, claims processing services, including pharmacy benefit management, and comprehensive health plan administration services. Together these services enable health systems to manage patient health in a more cost-effective manner. The Company’s contracts are structured as a combination of advisory fees, monthly member service fees, percentage of plan premiums and shared medical savings arrangements. The Company’s wholly-owned subsidiary, True Health New Mexico, Inc. (“True Health”) operates as a separate segment and is a commercial health plan we operate in New Mexico that focuses on small and large businesses. The Company’s headquarters is located in Arlington, Virginia. Our predecessor, Evolent Health Holdings, Inc. (“Evolent Health Holdings”), merged with and into Evolent Health, Inc. in connection with the offering reorganization which occurred on June 4, 2015 (the “Offering Reorganization”), as discussed in our 2017 Form 10-K. Prior to our initial public offering (“IPO”) in June 2015 and the Offering Reorganization we undertook in connection therewith, Evolent Health Holdings did not control Evolent Health LLC, our operating subsidiary company due to certain participating rights granted to our investor, TPG Global, LLC and certain of its affiliates (“TPG”). However, Evolent Health Holdings was able to exert significant influence on Evolent Health LLC and, accordingly, accounted for its investment in Evolent Health LLC using the equity method of accounting through June 3, 2015. Subsequent to the Offering Reorganization, the financial results of Evolent Health LLC have been consolidated in the financial statements of Evolent Health, Inc. Following the Offering Reorganization, the IPO, various securities offerings and sales (as described in Note 4 ) and acquisitions (as described in Note 4 ), as of September 30, 2018 , Evolent Health, Inc. owned 99.0% of Evolent Health LLC, holds 100% of the voting rights, is the sole managing member and, therefore, controls its operations. Since its inception, the Company has incurred losses from operations. As of September 30, 2018 , the Company had cash and cash equivalents of $221.8 million . The Company believes it has sufficient liquidity for the next 12 months as of the date the financial statements were available to be issued.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles	Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The Consolidated Balance Sheet at December 31, 2017 , has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2017 Form 10-K. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2017 Form 10-K for a complete summary of our significant accounting policies. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets, liabilities, consideration related to business combinations and asset acquisitions, revenue recognition including variable consideration, discounts and credits, estimated selling prices for performance obligations in contracts with multiple performance obligations, claims reserves, contingent payments, allowance for doubtful accounts, depreciable lives of assets, impairment of long lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and the useful lives of intangible assets. Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. Operating Segments Operating segments are defined as components of a business that earn revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of our technology-enabled services platform that supports our various value-based operations, such as delivery network alignment, population health performance, integrated cost and revenue management solutions and financial and administrative management services. Our True Health segment consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. See Note 17 for a discussion of our operating results by segment. Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. See “Changes in Accounting Principles” below for our updated revenue recognition policy as a result of our adoption of Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as short-term deferred revenue on our Consolidated Balance Sheets. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: As of As of September 30, December 31, 2018 2017 Collateral for letters of credit for facility leases (1) $ 3,710 $ 3,812 Collateral with financial institutions (2) 22,028 24,725 Claims processing services (3) 8,942 26,286 Collateral for reinsurance agreement (4) 10,000 10,000 Other 1,042 862 Total restricted cash and restricted investments 45,722 65,685 Current restricted investments — 8,150 Current restricted cash 42,328 54,248 Total current restricted cash and restricted investments 42,328 62,398 Noncurrent restricted investments 712 605 Noncurrent restricted cash 2,682 2,682 Total noncurrent restricted cash and restricted investments $ 3,394 $ 3,287 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 9 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing arrangements. As of September 30, 2018 , and December 31, 2017 , approximately $22.0 million and $16.6 million of the collateral amount was in a trust account and invested in a money market fund. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 15 for further discussion of our fair value measurement. As of December 31, 2017 , approximately $8.2 million of the collateral amount was invested in restricted certificates of deposit with remaining maturities of less than 12 months. The restricted investments are classified as held-to-maturity and stated at amortized cost. Fair value of the certificates of deposit is determined using Level 2 inputs and approximates amortized cost as of December 31, 2017 . See Note 9 for further discussion of our risk-sharing arrangements. (3) Represents cash held by Evolent on behalf of partners for claims processing services. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. (4) Represents restricted cash required as part of our capital only reinsurance agreement to provide balance sheet support to NMHC. There is no transfer of underwriting risk to Evolent and we are not at risk for any cash payments on behalf of NMHC as part of the agreement. The reinsurance agreement is further discussed in Note 9 . As of September 30, 2018 , the full $10.0 million amount was invested in a money market fund. The amount invested in the money market fund is considered restricted cash and is carried at fair value, which approximates cost. As of December 31, 2017 , the full $10.0 million amount was held in a FDIC participating bank account. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. As of September 30, As of December 31, 2018 2017 2017 2016 Cash and cash equivalents $ 221,837 $ 287,143 $ 238,433 $ 134,563 Restricted cash and restricted investments 45,722 16,932 65,685 40,416 Restricted investments included in restricted cash and restricted investments (712 ) (8,150 ) (8,755 ) (4,950 ) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 266,847 $ 295,925 $ 295,363 $ 170,029 Notes Receivable Notes receivable are carried at the face amount of each note plus respective accrued interest receivable, less received payments. The Company does not typically carry notes receivable in the course of its regular business, but contributed $20.0 million in the form of an implementation funding loan (the “Implementation Loan”) under an agreement with a current customer entered during the year ended December 31, 2017 . The Implementation Loan is expected to support implementation services to assist the customer in expanding its Medicaid membership. The Implementation Loan carries a fixed interest rate of 2.5% per annum and the terms of the agreement governing the Implementation Loan require it to be repaid in ten equal monthly installments of $2.0 million , plus accrued interest, during 2018. As of September 30, 2018 , the outstanding principal balance of the Implementation Loan was $6.0 million , excluding approximately $0.1 million of accrued interest. As of December 31, 2017 , the outstanding principal balance of the Implementation Loan was $20.0 million , excluding approximately $0.1 million of accrued interest. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The Company acquired additional intangible assets in conjunction with a strategic acquisition made during 2018. Information regarding the determination and allocation of the fair value of the acquired assets and liabilities is further described within Note 4 . The following summarizes the estimated useful lives by asset classification: Corporate trade name 20 years Customer relationships 15-25 years Technology 5 years Provider network contracts 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 7 for additional discussion regarding our intangible assets. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. Goodwill is assigned to the reporting unit that benefits from the synergies arising from each business combination. Foreign Currency The Company established an international subsidiary during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and average rates of exchange for revenue, costs, and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. We recorded a foreign currency translation loss of $0.1 million and $0.3 million on our Consolidated Statements of Operations for the three and nine months ended September 30, 2018 , which resulted in an “Accumulated other comprehensive loss” of $0.3 million on our Consolidated Balance Sheet as of September 30, 2018 . Changes in Accounting Principles Adoption of ASU 2014-09, Revenue from Contracts with Customers As discussed in Note 3 , the Company adopted ASU 2014-09, Revenue from Contracts with Customers, effective January 1, 2018. The following is our updated accounting policy with respect to revenue recognition for our Services segment. Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-Step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition on our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Transformation Services Revenue Transformation services consist of strategic assessments, or Blueprint contracts, and implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Platform and Operations Services Revenue Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers. Generally we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically include a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue for platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement. In accordance with the requirements under ASU 2014-09, the impact of adoption to our consolidated financial statements was as follows. See Note 5 for additional disclosures regarding Evolent's contracts with customers. Condensed Consolidated Statements of Operations (unaudited, in thousands) For the Three Months Ended September 30, 2018 Amounts without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Revenue Transformation services $ 9,230 $ 9,556 $ (326 ) Platform and operations services 118,094 117,942 152 Expenses Cost of revenue (exclusive of depreciation and amortization presented separately below) 73,967 77,409 (3,442 ) Selling, general and administrative expenses 59,566 59,676 (110 ) Income (loss) before income taxes and non-controlling interests (12,420 ) (15,798 ) 3,378 For the Nine Months Ended September 30, 2018 Amounts without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Revenue Transformation services $ 23,950 $ 25,272 $ (1,322 ) Platform and operations services 341,258 339,485 1,773 Expenses Cost of revenue (exclusive of depreciation and amortization presented separately below) 214,945 218,786 (3,841 ) Selling, general and administrative expenses 172,495 173,644 (1,149 ) Income (loss) before income taxes and non-controlling interests (36,622 ) (42,063 ) 5,441 Condensed Consolidated Balance Sheets (unaudited, in thousands) As of September 30, 2018 Balances without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Assets Accounts receivable, net $ 60,054 $ 57,848 $ 2,206 Contract assets (current) 3,705 — 3,705 Contract assets (noncurrent) 1,000 — 1,000 Contract cost assets 14,252 — 14,252 Liabilities and Shareholders' Equity (Deficit) Liabilities Deferred revenue $ 22,360 $ 24,100 $ (1,740 ) Other long-term liabilities 10,885 10,746 139 Shareholders' Equity (Deficit) Retained earnings (accumulated deficit) 66,696 44,580 22,116 Non-controlling interests 10,008 9,361 647 Adoption of ASU 2016-18, Statement of Cash Flows: Restricted Cash The Company adopted ASU 2016-18, Statement of Cash Flows: Restricted Cash, effective December 31, 2017, using the retroactive transition method, which resulted in the recast of our statement of cash flows for each period presented. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2017 Form 10-K for further information about the adoption. The amendments in the ASU require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A significant portion of the Company’s restricted cash consists of cash held on behalf of partners for claims processing services. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. Under the previous standard, there was no net impact to the statement of cash flows related to these amounts as the changes in accounts payable and accounts receivable were offset by the change in restricted cash. Upon adoption of ASU 2016-18, the change in restricted cash held on behalf of partners for claims processing would no longer net to zero, thereby potentially having a significant impact on cash flows from operations period over period. Given the pass-through nature of these claim payments, the change in restricted cash held on behalf of partners for claims processing is presented within cash flows from financing activities on our statements of changes in cash flows. The following table summarizes the impact of the change in accounting principle to the Company’s Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 (in thousands): For the Nine Months Ended September 30, 2017 As Reported Adjustments As Adjusted Cash Flows from Investing Activities Purchases and maturities of restricted investments $ — $ (3,200 ) $ (3,200 ) Change in restricted cash and restricted investments (2,164 ) 2,164 — Net cash and restricted cash provided by (used in) investing activities 17,003 (1,036 ) 15,967 Cash Flows from Financing Activities Change in restricted cash held on behalf of partners for claims processing — (25,648 ) (25,648 ) Net cash and restricted cash provided by (used in) financing activities 169,570 (25,648 ) 143,922 Net increase (decrease) in cash and cash equivalents and restricted cash 152,580 (26,684 ) 125,896 Cash and cash equivalents and restricted cash as of beginning-of-period 134,563 35,466 170,029 Cash and cash equivalents and restricted cash as of end-of-period $ 287,143 $ 8,782 $ 295,925

Recently Issued Accounting Stan

Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards Adoption of New Accounting Standards In June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting . The update expands the scope of ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU specifies that ASC 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments in the update also clarify that ASC 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. The update is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. We adopted the requirements of this standard effective July 1, 2018, and there was no impact to our financial condition and results of operations for the three and nine months ended September 30, 2018 . Going forward, we do not expect the adoption to have a material impact on our financial condition or results of operations. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , in order to clarify the principles of recognizing revenue. This standard establishes the core principle of recognizing revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB defines a five-step process that systematically identifies the various components of the revenue recognition process, culminating with the recognition of revenue upon satisfaction of an entity’s performance obligations. By completing all five steps of the process, the core principles of revenue recognition will be achieved. The new revenue standard (including updates) is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The guidance permits two methods of adoption: i) the full retrospective method applying the standard to each prior reporting period presented, or ii) the modified retrospective method with a cumulative effect of initially applying the guidance recognized at the date of initial application. The standard also allows entities to apply certain practical expedients at their discretion. The Company adopted the standard effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (“ASC 605”). The adoption of this standard resulted in changes related to revenue recognition for contracts that contain certain features, such as variable consideration. These changes generally accelerate revenue recognition. In addition, certain customer setup costs, which have historically been expensed as incurred, will now be capitalized. Evolent recognized the cumulative effect of applying the new revenue standard as a $17.3 million adjustment to the opening balance of retained earnings, including non-controlling interests, in the first quarter of 2018, primarily as a result of capitalization of expenses related to contract acquisition and fulfillment costs and acceleration of revenue due to variable consideration estimation. See Note 5 for additional disclosures regarding Evolent's contracts with customers. See Note 2 for updated revenue recognition accounting policy and the impact of adopting the new revenue recognition standard on Evolent’s financial statements. Future Adoption of New Accounting Standards In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customers Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact of adoption on our financial condition and results of operations. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We intend to adopt the requirements of this standard effective January 1, 2020, and are currently evaluating the impact of the adoption on our financial condition and results of operations. In February 2016, the FASB issued ASU 2016-02, Leases , which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight‑line basis over the term of the lease, respectively. A lessee is also required to record a right‑of‑use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (ASC Topic 842) supersedes the previous leases standard, ASC 840, Leases . The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has formulated an implementation team that is currently engaged in the evaluation process. We intend to adopt the requirements of this standard effective January 1, 2019, using a modified retrospective approach. We expect to take advantage of the package of practical expedients permitted within the new standard. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. Pursuant to ASU 2018-11, the Company will apply the new standard at its adoption date rather than at the earliest comparative period presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of retaining earnings. We anticipate that this standard will result in a material increase in the assets and liabilities on our consolidated balance sheets; however, we do not believe adoption will have a material impact on our results of operations.

Transactions

Transactions	9 Months Ended
	Sep. 30, 2018
Organizational Transactions [Abstract]
Transactions	Transactions Business Combinations New Mexico Health Connections On January 2, 2018 , the Company, through its wholly-owned subsidiary, True Health, completed its previously announced acquisition of assets related to NMHC’s commercial, small and large group business. The assets include a health plan management services organization with a leadership team and employee base with experience working locally with providers to run NMHC’s suite of preventive, disease and care management programs. The consideration paid by the Company in connection with the acquisition consisted of $10.3 million in cash (subject to certain adjustments), of which $0.3 million was deposited in an escrow account. This acquisition is expected to allow the Company to leverage its platform to support a value-based, provider-centric model of care in New Mexico. The Company commenced operations of the commercial health plan and began reporting the results of True Health as a new reportable segment during the first quarter of 2018. See Note 17 for further information about the Company’s segment reporting. At the time of the acquisition, the Company also entered into a managed services agreement (“MSA”) with NMHC to support its ongoing business. During the fourth quarter of 2017, the Company also entered into a reinsurance agreement with NMHC to provide balance sheet support. See Note 9 for further discussion of the reinsurance agreement. The MSA and reinsurance agreement were considered separate transactions and accounted for outside of the business combination. Therefore, there is no allocation of purchase price to these agreements at fair value. The Company incurred approximately $1.2 million in transaction costs related to the NHMC transaction, materially all of which were recorded within “Selling, general and administrative expenses” on our Consolidated Statements of Operations for the year ended December 31, 2017. The transaction was accounted for as a business combination using purchase accounting. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 2, 2018 , as follows (in thousands): Purchase consideration Cash paid to NMHC $ 10,000 Cash paid to escrow agent 252 Total consideration $ 10,252 Identifiable intangible assets acquired and liabilities assumed Customer relationships $ 2,700 Provider network contracts 2,300 Above market lease (100 ) Accrued compensation and employee benefits (474 ) Goodwill 5,826 Net assets acquired $ 10,252 Identifiable intangible assets associated with customer relationships and provider network contracts will be amortized on a straight-line basis over their estimated useful lives of 15 and 5 years, respectively. The customer relationships represent existing contracts in place to provide health plan services to a number of large and small group customers throughout the state of New Mexico. The provider network contracts represent a network of hospitals and physicians to service the health plan customers. The fair value of the customer relationship intangible asset was primarily determined using the income approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The fair value of the provider network intangible asset was primarily determined using the cost approach. The cost approach estimates the fair value for an asset based on the amount it would cost to replace the asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. Goodwill associated with the acquisition of True Health is allocated entirely to the True Health segment. The goodwill is attributable primarily to the acquired workforce and expected cost synergies, none of which qualify for recognition as a separate intangible asset. Goodwill is considered an indefinite-lived asset. The transaction is an asset acquisition for tax purposes, and as such the tax-basis in the acquired assets is equal to the book-basis fair value calculated and is recorded at the True Health legal entity. Therefore, no opening balance sheet deferred tax liability was recorded. The amounts above reflect management’s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed based on a valuation performed using currently available information. Any remaining adjustments are expected to be finalized within one year of the acquisition date. True Health is a separate segment, and its results of operations are provided in Note 17 - Segment Reporting. Pro Forma Financial Information (Unaudited) The unaudited pro forma Consolidated Statements of Operations presented below gives effect to the NMHC transaction as if it took place on January 1, 2017. The following pro forma information includes adjustments to: • reclassify transaction costs related to the NMHC transaction to the period beginning January 1, 2017; • record revenue and expenses related to the MSA beginning January 1, 2017; and • record amortization expenses related to intangible assets beginning January 1, 2017, for intangible assets acquired as part of the NMHC transaction. This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands, except per share data). For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Revenue $ 149,947 $ 129,820 $ 433,959 $ 378,801 Net income (loss) (12,555 ) (11,320 ) (36,651 ) (65,113 ) Net income (loss) attributable to non-controlling interests (126 ) (413 ) (680 ) (8,414 ) Net income (loss) attributable to Evolent Health, Inc. (12,429 ) (10,907 ) (35,971 ) (56,699 ) Net income (loss) per Common Share available to common shareholders Basic $ (0.16 ) $ (0.16 ) $ (0.47 ) $ (0.93 ) Diluted (0.16 ) (0.16 ) (0.47 ) (0.93 ) Securities Offerings and Sales Under an exchange agreement we entered into at the time of our IPO, we granted TPG, The Advisory Board Company (“The Advisory Board”) and Ptolemy Capital, LLC (“Ptolemy Capital”) (together, the “Investor Stockholders”) an exchange right that allows receipt of newly-issued shares of the Company’s Class A common stock in exchange (a “Class B Exchange”) for an equal number of shares of the Company’s Class B common stock (which are subsequently canceled) and an equal number of Evolent Health LLC’s Class B common units (“Class B units”). Class B units received by the Company from relevant Investor Stockholders are simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC cancels the Class B units it receives in the Class B Exchange. The cancellation of the Class B units results in an increase in the Company’s economic interest in Evolent Health LLC. March and June 2018 Private Sales In March 2018, The Advisory Board sold 3.0 million shares of the Company’s Class A common Stock in a private sale (the “March 2018 Private Sale”). The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company’s Class A common stock owned by The Advisory Board and 1.8 million newly-issued shares of the Company’s Class A common stock received by The Advisory Board pursuant to a Class B Exchange for all of its outstanding shares of the Company’s Class B common stock and Class B units. The Company did not receive any proceeds from the March 2018 Private Sale. Subsequent to this Class B Exchange, in June 2018, The Advisory Board sold all of their remaining shares of the Company’s Class A common stock and no longer owns any shares of our Class A common stock. As a result of this Class B Exchange and Evolent Health LLC’s cancellation of the Class B units during the March 2018 Private Sale, the Company’s economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. August 2017 Primary Offering In August 2017, the Company completed a primary offering of 8.8 million shares of its Class A common stock at a price to the public of $19.85 per share and a corresponding price to the underwriters of $19.01 per share (the “August 2017 Primary”). This offering resulted in net cash proceeds to the Company of approximately $166.9 million (gross proceeds of $175.0 million , net of $8.1 million in underwriting discounts and stock issuance costs). For each share of Class A common stock issued by Evolent Health, Inc., the Company received a corresponding Class A common unit from Evolent Health LLC in exchange for contributing the issuance proceeds to Evolent Health LLC. As a result of the Class A common stock and Class A common units issued during the August 2017 Primary, the Company’s economic interest in Evolent Health LLC increased from 96.1% to 96.6% immediately following the August 2017 Primary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. Secondary Offerings The Investor Stockholders initiated several Class B Exchanges as part of various secondary offerings during 2017, thus increasing the Company’s economic interest in Evolent Health LLC, as discussed below. The Company did not receive any proceeds from the secondary offerings described below. June 2017 Secondary Offering In June 2017, the Company completed a secondary offering of 4.5 million shares of its Class A common stock at a price to the underwriters of $25.87 per share (the “June 2017 Secondary”). The shares sold in the June 2017 Secondary consisted of 0.7 million existing shares of the Company’s Class A common stock owned and held by certain Investor Stockholders and 3.8 million newly-issued shares of the Company’s Class A common stock received by certain Investor Stockholders pursuant to Class B Exchanges. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the Class B units during the June 2017 Secondary, the Company’s economic interest in Evolent Health LLC increased from 90.5% to 96.1% immediately following the June 2017 Secondary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. May 2017 Secondary Offering In May 2017, the Company completed a secondary offering of 7.0 million shares of its Class A common stock at a price to the underwriters of $24.30 per share (the “May 2017 Secondary”). The shares were sold by the Investor Stockholders and certain management selling stockholders (together with the Investor Stockholders, the “Selling Stockholders”). The shares sold in the May 2017 Secondary consisted of 3.1 million existing shares of the Company’s Class A common stock owned and held by the Selling Stockholders, 3.8 million newly-issued shares of the Company’s Class A common stock received by certain Investor Stockholders pursuant to Class B Exchanges and 0.1 million shares issued upon the exercise of options by certain management selling stockholders. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the Class B units during the May 2017 Secondary, the Company’s economic interest in Evolent Health LLC increased from 84.9% to 90.5% immediately following the May 2017 Secondary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. March 2017 Secondary Offering In March 2017, the Company completed a secondary offering of 7.5 million shares of its Class A common stock at a price to the underwriters of $19.53 per share (the “March 2017 Secondary”). The shares sold in the March 2017 Secondary consisted of 3.1 million existing shares of the Company’s Class A common stock owned and held by the Investor Stockholders and 4.4 million newly-issued shares of the Company’s Class A common stock received by certain Investor Stockholders pursuant to Class B Exchanges. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the Class B units during the March 2017 Secondary, the Company’s economic interest in Evolent Health LLC increased from 77.4% to 83.9% immediately following the March 2017 Secondary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. In connection with the March 2017 Secondary, the underwriters exercised, in full, their option to purchase an additional 1.1 million shares of Class A common stock (the “March 2017 Option to Purchase Additional Shares”) from the Investor Stockholders at a price of $19.53 per share. The March 2017 Option to Purchase Additional Shares closed in May 2017. The shares sold in the March 2017 Option to Purchase Additional Shares consisted of 0.5 million existing shares of the Company’s Class A common stock owned and held by certain Investor Stockholders. It also included 0.6 million newly-issued shares of the Company’s Class A common stock received by certain Investor Stockholders pursuant to Class B Exchanges. As a result of the Class B Exchanges and Evolent Health LLC’s cancellation of the Class B units during the March 2017 Option to Purchase Additional Shares, the Company’s economic interest in Evolent Health LLC increased from 83.9% to 84.9% immediately following the March 2017 Option to Purchase Additional Shares, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. The June 2017 Secondary, May 2017 Secondary, March 2017 Secondary and March 2017 Option to Purchase Additional Shares are collectively referred to as the “2017 Secondary Offerings.” The Company’s economic interest in Evolent Health LLC will increase if further Class B Exchanges occur. Asset Acquisitions Accordion Health, Inc. On June 8, 2017 , the Company entered into an agreement to acquire Accordion Health, Inc. (“Accordion”) for $3.2 million (the “Accordion Purchase Agreement”). Accordion provides technology that the Company believes enhances its risk-adjustment factor services to its partners. In addition to technology assets, the software development team from Accordion joined Evolent as full-time employees. Under the terms of the Accordion Purchase Agreement, members of the software development team will be eligible for an additional $0.8 million earn-out, contingent upon the completion of specified software development targets. We accounted for the transaction as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identified asset, thus satisfying the requirements of the screen test introduced in ASU 2017-01. The assets acquired in the transaction were measured based on the amount of cash paid to Accordion, including transaction costs, as the fair value of the assets given was more readily determinable than the fair value of the assets received. We classified and designated the identifiable assets acquired as a $3.3 million technology intangible asset, inclusive of approximately $0.1 million of capitalized transaction costs. We also assessed and determined the useful life of the acquired intangible assets to be five years, subject to amortization. The Company will account for the contingent earn-out as a post-acquisition expense as the specified software development targets are achieved. The transaction was a taxable stock acquisition and the Company recognized deferred tax liability of $2.0 million related to the book-tax basis difference in the acquired asset, which resulted in a $2.0 million increase in the value of the intangible asset. The additional deferred tax liability represents a future source of taxable income that enables the Company to release some of its previously established valuation allowance, the reduction of which is accounted for outside of acquisition accounting, resulting in income tax benefit.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition As discussed in Note 3 , we adopted ASU 2014-09, effective January 1, 2018, which introduces ASC 606. See Note 2 for the updated revenue recognition policy and the impact of adopting the new revenue recognition standard on the Company’s financial statements. The following are other relevant disclosures as required by the adoption of ASU 2014-09. Provisions within ASC 606 are only applicable to revenues derived from our Services segment. Disaggregation of Revenue The following table represents Evolent’s Services segment revenue disaggregated by revenue type for the three and nine months ended September 30, 2018 (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2018 Services Revenue Transformation services $ 9,230 $ 23,950 Platform and operations services 116,226 335,509 Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term that is greater than one year, we have allocated approximately $125.0 million of transaction price to performance obligations that are unsatisfied or partially unsatisfied as of September 30, 2018 . We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2 . We expect to recognize revenue on approximately 60% and 84% of these remaining performance obligations by December 31, 2019, and December 31, 2020, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of this revenue that we actually receive may be less than this estimate. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or noncurrent based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within “Contract assets” on our consolidated balance sheets. Our current accounts receivable are classified within “Accounts receivable, net” on our consolidated balance sheets and our noncurrent accounts receivable are classified within “Prepaid expenses and other noncurrent assets” on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within “Deferred revenue” on our consolidated balance sheets, and noncurrent deferred revenue is recorded within “Other long-term liabilities” on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): As of As of September 30, January 1, 2018 2018 Short-term receivables (1) $ 58,190 $ 47,131 Long-term receivables (1) 6,550 — Short-term contract assets 3,705 3,710 Long-term contract assets 1,000 1,791 Short-term deferred revenue 22,360 26,147 Long-term deferred revenue 1,000 493 (1) Excludes pharmacy claims receivable and premiums receivable During the nine months ended September 30, 2018 , our contract asset balance decreased by $0.8 million , primarily as the right to the consideration became unconditional and the associated balance is reclassified to accounts receivable. During the nine months ended September 30, 2018 , our deferred revenue decreased by $3.3 million , primarily as a result of the recognition of variable consideration estimate. The amount of revenue recognized during the three and nine months ended September 30, 2018 , from amounts included in deferred revenue at the beginning of the period was $3.7 million and $17.0 million , respectively. The amount of revenue recognized during the three and nine months ended September 30, 2018 from performance obligations satisfied (or partially satisfied) in previous periods, due primarily to net gain share as well as other estimates, was $9.4 million and $11.5 million , respectively. Contract Costs Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as noncurrent assets and recorded within “Contract cost assets” on our consolidated balance sheets. Amortization expense is recorded within “Selling, general and administrative expenses” on the accompanying consolidated statements of operations. As of September 30, 2018 , the Company had $2.0 million of contract acquisition cost assets, net of accumulated amortization, and amortiza tion expense of $0.1 million and $0.2 million for the three and nine months ended September 30, 2018 , respectively. In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as noncurrent and recorded within “Contract cost assets” on our consolidated balance sheets. Amortization expense is recorded within “Cost of revenue” on the accompanying consolidated statements of operations. As of September 30, 2018 , the Company had $12.3 million of contract fulfillment cost assets, net of accumulated amortization, and amortization expense of $0.6 million and $1.7 million for the three and nine months ended September 30, 2018 , respectively. The majority of the contract cost balance was recorded as part of the transition adjustment that was recorded upon implementation of ASC 606. These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net The following summarizes our property and equipment (in thousands): As of As of September 30, December 31, 2018 2017 Computer hardware $ 8,602 $ 5,667 Furniture and equipment 3,038 2,448 Internal-use software development costs 73,679 48,557 Leasehold improvements 9,638 8,708 Total property and equipment 94,957 65,380 Accumulated depreciation and amortization (26,265 ) (14,458 ) Total property and equipment, net $ 68,692 $ 50,922 The Company capitalized $7.0 million and $25.1 million of internal-use software development costs for the three and nine months ended September 30, 2018 , respectively, and $8.4 million and $20.4 million for the three and nine months ended September 30, 2017 , respectively. The net book value of capitalized internal-use software development costs was $58.7 million and $42.1 million as of September 30, 2018 , and December 31, 2017 , respectively. Depreciation expense related to property and equipment was $4.3 million and $11.8 million for the three and nine months ended September 30, 2018 , respectively, of which amortization expense related to capitalized internal-use software development costs was $3.1 million and $8.5 million , respectively. Depreciation expense related to property and equipment was $2.3 million and $6.0 million for the three and nine months ended September 30, 2017 , respectively, of which amortization expense related to capitalized internal-use software development costs was $1.2 million and $2.8 million , respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company has two reporting units: Services and True Health. Our annual goodwill impairment review occurs during the fourth quarter of each fiscal year. In interim periods between annual goodwill reviews, we also evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in strategy, partners, or litigation. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the nine months ended September 30, 2018 . We will perform our annual impairment test as of October 31, 2018 . The following tables summarize the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Nine Months Ended September 30, 2018 Services True Health Consolidated Balance as of beginning-of-period (1) $ 628,186 $ — $ 628,186 Goodwill Acquired (2) 1,234 5,826 7,060 Measurement period adjustments (2) 4 — 4 Foreign currency translation (2) (162 ) — (162 ) Balance as of end-of-period $ 629,262 $ 5,826 $ 635,088 (1) Net of cumulative inception to date impairment of $160.6 million . (2) Goodwill acquired, measurement period adjustments and foreign currency translation are all related to transactions completed during the first quarter of 2018. For the Year Ended December 31, 2017 (1) Balance as of beginning-of-period (2) $ 626,569 Measurement period adjustments (3) 1,617 Balance as of end-of-period $ 628,186 (1) All of the goodwill was allocated to the Services segment as of December 31, 2017, as the True Health segment was not established until the first quarter of 2018. (2) Net of cumulative inception to date impairment of $160.6 million . (3) Represents measurement period adjustments related to Valence Health and Aldera. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 4” in our 2017 Form 10-K for further information regarding the Valence Health and Aldera transactions. Intangible Assets, Net Details of our intangible assets (in thousands) are presented below: As of September 30, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 16.7 $ 19,000 $ 3,166 $ 15,834 Customer relationships (1) 19.5 208,719 25,550 183,169 Technology 2.4 55,933 27,264 28,669 Below market lease, net 4.3 4,097 2,918 1,179 Provider network contracts 4.3 2,300 345 1,955 Total $ 290,049 $ 59,243 $ 230,806 (1) The increase in the gross carrying amount of the customer relationships intangible is attributable to $2.7 million of acquired customer relationships from the NMHC transaction and $2.5 million related the Vestica Healthcare LLC (“Vestica”) transaction. The Company acquired certain assets from Vestica in March 2016. The transaction included additional consideration of up to $4.0 million , which was being held in escrow and was recorded within “Prepaid expenses and other noncurrent assets” on our Consolidated Balance Sheets. In February 2018, the Company and Vestica reached an agreement to settle $3.5 million of the $4.0 million in escrow. Based on the terms of the settlement agreement, the Company reclassified the unamortized portion of the additional consideration from “Prepaid expenses and other noncurrent assets” into “Customer relationships” as of the settlement date. See Note 4 for further information about the NMHC transaction and see “ Part II - Item 8. Financial Statements and Supplementary Data - Note 4 ” of our 2017 Form 10-K for further information about the Vestica transaction. As of December 31, 2017 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 17.4 $ 19,000 $ 2,454 $ 16,546 Customer relationships 20.5 203,500 18,312 185,188 Technology 3.1 55,802 17,810 37,992 Below market lease, net 4.8 4,197 2,662 1,535 Total $ 282,499 $ 41,238 $ 241,261 Amortization expense related to intangible assets was $6.1 million and $18.0 million for the three and nine months ended September 30, 2018 , respectively, and $5.3 million and $15.0 million for the three and nine months ended September 30, 2017 , respectively. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during nine months ended September 30, 2018 , that would require an impairment test for our intangible assets.

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2021 Notes were issued at par for net proceeds of $120.4 million . We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016 . Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017 , at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021 , unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest. Upon maturity, and at the option of the holders of the 2021 Notes, the principal amount of the notes may be settled via shares of the Company’s Class A common stock. For the three and nine months ended September 30, 2018 and 2017 , the Company recorded approximately $0.6 million and $1.9 million , respectively, in interest expense and $0.2 million and $0.7 million , respectively, in non-cash interest expense related to the amortization of deferred financing costs. The 2021 Notes are convertible into shares of the Company’s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company’s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the indenture between Evolent Health, Inc. and U.S. Bank National Association, as trustee, related to the 2.00% convertible senior notes due 2021, dated as of December 5, 2016). The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date. Convertible Senior Notes Carrying Value While the 2021 Notes are recorded on our accompanying unaudited interim consolidated balance sheets at their net carrying value of $122.1 million as of September 30, 2018 , the 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act of 1933, as amended) and their fair value was $169.1 million , based on a traded price on September 28 , 2018, a Level 2 input. The fair value as of December 31, 2017 , was $120.4 million , based on a traded price on December 29, 2017, a Leve l 2 input. The 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term debt (in thousands): As of As of September 30, December 31, 2018 2017 Carrying value $ 122,082 $ 121,394 Unamortized discount 2,918 3,606 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 3.2 3.9

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. These payment obligations are obligations of the Company. For purposes of the TRA, the benefit deemed realized by the Company will be computed by comparing its actual income tax liability to the amount of such taxes that the Company would have been required to pay had there been no increase to the tax basis of the assets of the Company as a result of the exchanges or had the Company had no NOL carryforward balance. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including: • the timing of the exchanges and the price of the Class A shares at the time of the transaction, triggering a tax basis increase in the Company’s asset and a corresponding benefit to be realized under the TRA; and • the amount and timing of our taxable income - the Company will be required to pay 85% of the tax savings as and when realized, if any. If the Company does not have taxable income, it will not be required to make payments under the TRA for that taxable year because no tax savings were actually realized. Due to the items noted above, and the fact that the Company is in a full valuation allowance position such that the deferred tax assets related to the Company’s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA. Litigation Matters We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. The Company is not aware of any legal proceedings or claims as of September 30, 2018 , that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company’s financial position or result of operations. Commitments Commitments to Equity-Method Investees The Company has contractual arrangements with its equity-method investees that will require the Company to provide operating capital support in the form of equity financing of up to $2.6 million as of September 30, 2018 , in accordance with the Company’s contribution agreements with its equity-method investees. These obligations are outside of Company’s control and payment could be requested during 2018. The Company did no t have any contingent commitments to equity-method investees as of December 31, 2017 . Letter of Credit During the first quarter of 2017, the Company entered into an agreement to provide a letter of credit, for up to $5.0 million , to assist a customer in demonstrating adequate reserves to the customer’s state regulatory authorities. The letter of credit is effective from September 30, 2017 through June 30, 2019, and carries a quarterly facility rental fee of 0.80% per annum on the amount of the outstanding balance. The letter of credit will terminate after June 30, 2019. The letter of credit is presented at the face amount plus accrued facility rental fee, less received payments. T here was no outstanding balance related t o this letter of credit as of September 30, 2018 , or December 31, 2017 . Lease Commitments The Company has entered into lease agreements for its primary office locations in Arlington, Virginia, Lisle, Illinois, Chicago, Illinois, Albuquerque, New Mexico and Pune, India. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. The Company also has several smaller leases in various locations within Texas and California. Total rental expense, net of sublease income, on operating leases was $3.3 million and $10.1 million for the three and nine months ended September 30, 2018 , respectively, and $3.0 million and $8.0 million for the three and nine months ended September 30, 2017 , respectively. In connection with various lease agreements, the Company is required to maintain $3.7 million in letters of credit and, as such, held $3.7 million in restricted cash and restricted investments as collateral for the letters of credit as of September 30, 2018 . Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements. Registration Rights Agreement We entered into a registration rights agreement with The Advisory Board, the University of Pittsburgh Medical Center (“UPMC”), TPG and another investor to register for sale under the Securities Act of 1933, as amended, shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016. Pursuant to certain terms of the registration rights agreement, certain Investor Stockholders sold 19.7 million shares of the Company’s Class A common stock during the 2017 Secondary Offerings, as discussed in Note 4 . The Company incurred $0.3 million and $1.5 million in expenses related to the 2017 Secondary Offerings for the three and nine months ended September 30, 2017 , pursuant to the terms of the registration rights agreement. The expenses were recorded within “Selling, general and administrative expenses” on our Consolidated Statements of Operations. We did not incur any expenses related to secondary offerings or other sales of shares by our Investor Stockholders for the three and nine months ended September 30, 2018 . We will continue to pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act of 1933, as amended, state law or otherwise. Guarantees As part of our strategy to support certain of our partners in the Next Generation Accountable Care Program, we entered into upside and downside risk sharing arrangements. Our downside risk-sharing arrangements are limited to our fees and are executed through our wholly-owned captive insurance company. To satisfy the capital requirements of our insurance entity as well as state insurance regulators, Evolent entered into letters of credit of $22.0 million as of September 30, 2018 , to secure potential losses related to insurance services. This amount is in excess of our actuarial assessment of loss. Reinsurance Agreement During the fourth quarter of 2017, the Company entered into a 15 -month, $10.0 million capital-only reinsurance agreement with NMHC, expiring on December 31, 2018. The purpose of the capital-only reinsurance is to provide balance sheet support to NMHC. There is no uncertainty to the outcome of the agreement as there is no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health is at risk for any cash payments on behalf of NMHC. As a result, this agreement does not qualify for reinsurance accounting. The Company will record a quarterly fee of approximately $0.2 million as non-operating income on its consolidated statements of operations and will maintain $10.0 million in restricted cash and restricted investments on its consolidated balance sheets for the duration of the reinsurance agreement. UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of September 30, 2018 , approximately 72.3% of our $266.8 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks, approximately 27.4% were held in money market funds and less than 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes those partners who represented at least 10.0% of our trade accounts receivable for the periods presented: As of As of September 30, December 31, 2018 2017 Customer B * 11.8 % Customer C 16.2 % 32.1 % Customer D * 16.5 % * Represents less than 10.0% of the respective balance In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners. The following table summarizes those partners who represented at least 10.0% of our revenue for the periods presented: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Customer A 18.8 % 19.0 % 18.9 % 18.5 % Customer B * * * 10.0 % * Represents less than 10.0% of the respective balance

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Net income (loss) $ (12,555 ) $ (13,129 ) $ (36,651 ) $ (55,977 ) Less: Net income (loss) attributable to non-controlling interests (126 ) (541 ) (680 ) (8,471 ) Net income (loss) available for common shareholders (1) (2) $ (12,429 ) $ (12,588 ) $ (35,971 ) $ (47,506 ) Weighted-average common shares outstanding (2) (3) 77,999 70,328 76,871 60,867 Earnings (Loss) per Common Share Basic $ (0.16 ) $ (0.18 ) $ (0.47 ) $ (0.78 ) Diluted (0.16 ) (0.18 ) (0.47 ) (0.78 ) (1) For periods of net loss, net income (loss) available for common shareholders is the same for both basic and diluted purposes. (2) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share. (3) For periods of net loss, shares used in the earnings (loss) per common share calculation represent basic shares as using diluted shares would be anti-dilutive. Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Exchangeable Class B common stock 766 2,654 1,251 8,846 Restricted stock units ("RSUs") 1,197 577 923 557 Stock options and performance-based stock options 2,698 2,976 2,486 3,031 Convertible senior notes 5,201 5,201 5,201 5,201 Total 9,862 11,408 9,861 17,635

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Award Type Stock options $ 2,139 $ 4,291 $ 7,009 $ 12,452 Performance-based stock options 113 113 334 335 RSUs 1,795 1,304 5,217 3,385 Total $ 4,047 $ 5,708 $ 12,560 $ 16,172 Line Item Cost of revenue $ 376 $ 401 $ 1,130 $ 1,143 Selling, general and administrative expenses 3,671 5,307 11,430 15,029 Total $ 4,047 $ 5,708 $ 12,560 $ 16,172 No stock-based compensation in the totals above was capitalized as software development costs for the three and nine months ended September 30, 2018 and 2017 , respectively. Stock-based awards were granted as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Stock options 3 84 1,054 961 RSUs 18 37 857 461

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year. The Company recorded $0.1 million and less than $0.1 million in income tax expense for the three and nine months ended September 30, 2018 , respectively, which resulted in effective tax rates of (0.9)% and (0.1)% , respectively. The Company recorded $1.7 million and $2.0 million in income tax benefit for the three and nine months ended September 30, 2017 , respectively, which resulted in effective tax rates of 11.6% and 3.5% , respectively. The income tax benefit recorded during the three and nine months ended September 30, 2018 , primarily relates to the change in indefinite-lived components and components expected to reverse outside of the net operating loss carryover period as part of the outside basis difference in our partnership interest in Evolent Health LLC. With the exception of these components, the Company continues to record a valuation allowance against the net deferred tax assets. As a result of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017 , and subsequent state jurisdictions conforming to certain provisions of the Tax Act with respect to the indefinite carryforward period and 80% taxable income limitation on NOLs arising after December 31, 2017, these components of the deferred tax liabilities are comprised of the entire nonconforming state indefinite-lived components and those outside of the NOL carryforward period and a portion of our federal and conforming states components that could not be used as a source of income. As of December 31, 2017 , the Company had recorded a provisional estimate of the financial statement impact of the Tax Act in accordance with SEC Staff Accounting Bulletin No. 118. During the three and nine months ended September 30, 2018 , the change in the initial provisional estimates is immaterial. The C ompany will continue to evaluate any further adjustments necessary through 2018. As a result of the increase in our ownership of Evolent Health LLC following the March 2018 Private Sale discussed in Note 4 above, the Company reduced the indefinite portion of the deferred tax liability related to the book basis compared to the tax basis in our partnership interest in Evolent Health LLC by approximately $0.9 million for the nine months ended September 30, 2018 . The effect of this change in the deferred tax liability was recorded as additional paid-in capital. As a result of the increase in our ownership of Evolent Health LLC following the August 2017 Primary and 2017 Secondary Offerings discussed in Note 4 above, the Company reduced the indefinite portion of the deferred tax liability related to the book basis compared to the tax basis in our partnership interest in Evolent Health LLC by $13.1 million for the nine months ended September 30, 2017 . The effect of this change in the deferred tax liability was recorded as $12.8 million of additional paid-in capital and $0.3 million of income tax benefit. As of December 31, 2017 , the Company had unrecognized tax benefits of $0.8 million that, if recognized, would not affect the effective tax rate. As of September 30, 2018 , the Company has released all unrecognized tax benefits due to the filing of a federal income tax automatic accounting method change application. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 9 above and “Part II - Item 8. Financial Statements and Supplementary Data - Note 12” in our 2017 Form 10-K for discussion of our TRA.

Investments In and Advances to

Investments In and Advances to Equity Method Investees	9 Months Ended
	Sep. 30, 2018
Equity Method Investments and Joint Ventures [Abstract]
Investments In and Advances to Equity Method Investees	Investments In and Advances to Equity Method Investees The Company has entered into joint venture agreements with various entities. As of September 30, 2018 , the Company’s economic and voting interests in these entities ranged between 4% and 40% . As of December 31, 2017 , the Company’s economic interests in these entities ranged between 26% and 40% and voting interests ranged between 27% and 40% . The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the losses from these investments was approximately $1.4 million and $2.8 million for the three and nine months ended September 30, 2018 , respectively, and $0.4 million and $1.4 million for the three and nine months ended September 30, 2017 , respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenues related to these services agreements was $5.1 million and $5.9 million for the three and nine months ended September 30, 2018 , respectively, and less than $0.1 million and $0.4 million for the three and nine months ended September 30, 2017 , respectively.

Non-controlling Interests

Non-controlling Interests	9 Months Ended
	Sep. 30, 2018
Noncontrolling Interest [Abstract]
Non-controlling Interests	Non-controlling Interests Immediately following the Offering Reorganization and IPO (as described in our 2017 Form 10-K), the Company owned 70.3% of Evolent Health LLC. The Company’s ownership percentage changes with the issuance of Class A common stock and Class B Exchanges. The Company completed the 2017 Secondary Offerings during 2017. The shares sold in the 2017 Secondary Offerings consisted of 20.1 million shares of the Company’s Class A common stock, consisting of 7.4 million existing shares of the Company’s Class A common stock owned and held by certain Selling Stockholders, 12.6 million newly-issued shares of the Company’s Class A common stock received by certain Investor Stockholders pursuant to Class B Exchanges and 0.1 million shares issued upon the exercise of options by certain management selling stockholders. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of its Class B common units during the 2017 Secondary Offerings, the Company’s economic interest in Evolent Health LLC increased from 77.4% to 96.1% immediately following the June 2017 Secondary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. In addition, the Company issued 8.8 million shares of its Class A Common Stock during the August 2017 Primary for net proceeds of $166.9 million . For each share of Class A common stock issued by Evolent Health, Inc., the Company received a corresponding Class A common unit from Evolent Health LLC in exchange for contributing the issuance proceeds to Evolent Health LLC. As a result of the Class A common stock and Class A common units issued in conjunction with the August 2017 Primary, the Company’s economic interest in Evolent Health LLC increased from 96.1% to 96.6% immediately following the August 2017 Primary, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. The Company completed the March 2018 Private Sale during March 2018. The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company’s Class A common stock owned and held by The Advisory Board and 1.8 million newly-issued shares of the Company’s Class A common stock received by The Advisory Board pursuant to a Class B Exchange. As a result of this Class B Exchange and Evolent Health LLC’s cancellation of the Class B units during the March 2018 Private Sale, the Company’s economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. As of September 30, 2018 , and December 31, 2017 , we owned 99.0% and 96.6% of the economic interests in Evolent Health LLC, respectively. See Note 4 for further discussion of the March 2018 Private Sale, August 2017 Primary and 2017 Secondary Offerings. Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Non-controlling interests as of beginning-of-period $ 10,148 $ 34,680 $ 35,427 $ 209,588 Cumulative-effect adjustment from adoption of new accounting principle — — 594 — Decrease in non-controlling interests as a result of Class B Exchanges — — (25,334 ) (168,883 ) Reclassification of non-controlling interests (14 ) 1,793 1 3,698 Net income (loss) attributable to non-controlling interests (126 ) (541 ) (680 ) (8,471 ) Non-controlling interests as of end-of-period $ 10,008 $ 35,932 $ 10,008 $ 35,932

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 41,186 $ — $ — $ 41,186 Restricted cash and restricted investments (1) 32,028 — — 32,028 Total $ 73,214 $ — $ — $ 73,214 Liabilities Contingent consideration (2) — — 8,300 8,300 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 60,535 $ — $ — $ 60,535 Restricted cash and restricted investments (1) 16,575 — — 16,575 Total $ 77,110 $ — $ — $ 77,110 Liabilities Contingent consideration (2) — — 8,700 8,700 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of September 30, 2018 , and December 31, 2017 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition as described below. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels for the three and nine month periods ended September 30, 2018 and 2017 , respectively. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. The strategic alliance with Passport includes a provision for additional equity consideration contingent upon the Company obtaining new third-party Medicaid business in future periods. The contingent consideration of $8.3 million and $8.7 million is a mark-to-market liability recorded within “Other long-term liabilities” on our Consolidated Balance Sheets as of September 30, 2018 , and December 31, 2017 . We recorded a re-measurement loss of approximately $0.1 million for the three months ended September 30, 2018 , and a re-measurement gain of approximately $0.4 million for the nine months ended September 30, 2018 , and re-measurement losses of approximately $0.1 million and $0.3 million for the three and nine months ended September 30, 2017 , respectively , based on changes in the underlying assumptions of the fair value calculation. T he fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Passport contingent consideration are the five -year risk-adjusted recurring revenue compound annual growth rate (“CAGR”) and the applicable discount rate. A significant increase in the assumed five -year risk-adjusted recurring revenue CAGR projection or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration. The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Balance as of beginning-of-period $ 8,200 $ 8,500 $ 8,700 $ 8,300 Realized and unrealized (gains) losses, net 100 100 (400 ) 300 Balance as of end-of-period $ 8,300 $ 8,600 $ 8,300 $ 8,600 The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: As of September 30, 2018 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration (1) $ 8,300 Real options approach Risk-adjusted recurring revenue CAGR 112.7 % (2) Discount rate/time value 3.8% - 4.5% (1) Related to additional Passport earn-out consideration as described above. (2) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rate is based on a theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR over the period 2019-2021 is 78.6% . As of December 31, 2017 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration (1) $ 8,700 Real options approach Risk-adjusted recurring revenue CAGR 92.5 % (2) Discount rate/time value 2.7% - 4.0% (1) Related to additional Passport earn-out consideration as described above. (2) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rate is based on a theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR over the period 2019-2021 is 19.2% . Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. See Notes 4 , 5 , 6 , 7 and 13 for further discussion of assets measured at fair value on a nonrecurring basis. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 8 for information regarding the fair value of the 2021 Notes.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Parties	Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements. As discussed in Note 13 , the Company has economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. Revenues related to these services agreements was $5.1 million and $5.9 million for the three and nine months ended September 30, 2018 , respectively, and less than $0.1 million and $0.4 million for the three and nine months ended September 30, 2017 , respectively. The Company also works closely with UPMC, one of its founding investors. The Company’s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest. Additionally, prior to the Offering Reorganization, we issued shares of our stock to certain of our partners while concurrently entering into revenue contracts with those partners. Those partners are considered related parties and the balances and/or transactions with them were reported on our consolidated financial statements for the periods in which they held a significant equity interest in Evolent Health, Inc. The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Revenue Transformation services $ 5,332 $ 352 $ 6,112 $ 597 Platform and operations services 12,180 9,411 27,072 24,764 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 2,390 5,299 6,842 17,382 Selling, general and administrative expenses 241 514 620 1,038

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting We define our reportable segments based on the way the chief operating decision maker (“CODM”), currently the Chief Executive Officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows: • Services, which consists of our technology-enabled services platform that supports our various value-based operations, such as delivery network alignment, population health performance, integrated cost and revenue management solutions and financial and administrative management services; and • True Health, which consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results. The CODM uses Adjusted Revenue and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. Adjusted Revenue and Adjusted EBITDA are segment performance financial measures that offer a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. Adjusted Revenue is defined as the sum of Adjusted Services Revenue and True Health premiums revenue less intersegment eliminations. Adjusted Services Revenue is defined as Services revenue adjusted to exclude the impact of purchase accounting adjustments. Adjusted Services Revenue consists of Adjusted Transformation Services Revenue and Adjusted Platform and Operations Services Revenue, which are defined as transformation services revenue and platform and operations services revenue, respectively, before the effect of intersegment eliminations and adjusted to exclude the impact of purchase accounting adjustments. The company’s Adjusted Services Revenue for the nine months ended September 30, 2018 , includes a $4.5 million adjustment related to revenue that was contracted for prior to 2018 and that was properly excluded from revenue in our 2017 results under the revenue recognition rules then in effect under ASC 605. On January 1, 2018, we adopted the new revenue recognition rules under ASC 606 using the modified retrospective method, which required us to include this $4.5 million as part of the cumulative transition adjustment to beginning retained earnings as of January 1, 2018. Under ASC 605, and based on proportionate performance revenue recognition, we would have recognized an additional $4.5 million in revenue during 2018, primarily within our Adjusted Transformation Services Revenue. The Company has therefore included this revenue, and related profit, in its adjusted results for the nine months ended September 30, 2018 , as they had not been previously reported prior to 2018 and the contracts are expected to be completed within 2018. This is a one-time adjustment and it will not reoccur in future periods. Adjusted EBITDA is the sum of Services Adjusted EBITDA and True Health Adjusted EBITDA and is defined as EBITDA (net income (loss) attributable to Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude changes in fair value of contingent consideration and indemnification assets, income (loss) from equity method investees, other income (expense), net, net (income) loss attributable to non-controlling interests, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, transaction costs related to acquisitions and business combinations and other one-time adjustments (which for the nine months ended September 30, 2018 , includes the ASC 606 transition adjustment described above). When Adjusted EBITDA is discussed in this report, the most directly comparable GAAP financial measure is net income (loss) attributable to Evolent Health, Inc. Management considers Adjusted Revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. The following tables present our segment information (in thousands): Intersegment Services True Health (1) Eliminations Consolidated Adjusted Revenue Three Months Ended September 30, 2018 Services: Adjusted Transformation Services $ 9,230 $ — $ — $ 9,230 Adjusted Platform and Operations Services 121,845 — (3,537 ) 118,308 Adjusted Services Revenue 131,075 — (3,537 ) 127,538 True Health: Premiums — 22,829 (206 ) 22,623 Adjusted Revenue 131,075 22,829 (3,743 ) 150,161 Purchase accounting adjustments (2) (214 ) — — (214 ) Total revenue $ 130,861 $ 22,829 $ (3,743 ) $ 149,947 Three Months Ended September 30, 2017 Services: Adjusted Transformation Services $ 8,204 $ — $ — $ 8,204 Adjusted Platform and Operations Services 100,157 — — 100,157 Adjusted Services Revenue 108,361 — — 108,361 Adjusted Revenue 108,361 — — 108,361 Purchase accounting adjustments (2) (449 ) — — (449 ) Total revenue $ 107,912 $ — $ — $ 107,912 Segments Services True Health (1) Total Three Months Ended September 30, 2018 Adjusted EBITDA $ 4,065 $ 732 $ 4,797 Three Months Ended September 30, 2017 Adjusted EBITDA $ 2,648 $ — $ 2,648 (1) The True Health segment was created in January 2018. (2) Purchase accounting adjustments pertain to Adjusted Platform and Operations Services Revenue. There were no purchase accounting adjustments in relation to Adjusted Transformation Services Revenue or True Health premiums revenue. Intersegment Services True Health (1) Eliminations Consolidated Adjusted Revenue Nine Months Ended September 30, 2018 Services: Adjusted Transformation Services $ 27,605 $ — $ — $ 27,605 Adjusted Platform and Operations Services 353,697 — (10,949 ) 342,748 Adjusted Services Revenue 381,302 — (10,949 ) 370,353 True Health: Premiums — 69,353 (602 ) 68,751 Adjusted Revenue 381,302 69,353 (11,551 ) 439,104 ASC 606 transition adjustment (2) (4,498 ) — — (4,498 ) Purchase accounting adjustments (3) (647 ) — — (647 ) Total revenue $ 376,157 $ 69,353 $ (11,551 ) $ 433,959 Nine Months Ended September 30, 2017 Services: Adjusted Transformation Services $ 23,799 $ — $ — $ 23,799 Adjusted Platform and Operations Services 298,646 — — 298,646 Adjusted Services Revenue 322,445 — — 322,445 Adjusted Revenue 322,445 — — 322,445 Purchase accounting adjustments (3) (1,224 ) — — (1,224 ) Total revenue $ 321,221 $ — $ — $ 321,221 Segments Services True Health (1) Total Nine Months Ended September 30, 2018 Adjusted EBITDA $ 16,674 $ 921 $ 17,595 Nine Months Ended September 30, 2017 Adjusted EBITDA $ (5,689 ) $ — $ (5,689 ) (1) The True Health segment was created in January 2018. (2) Adjustment to Adjusted Transformation Services Revenue was approximately $3.7 million and the adjustment to Adjusted Platform and Operations Services Revenue was approximately $0.8 million . (3) Purchase accounting adjustments pertain to Adjusted Platform and Operations Services Revenue. There were no purchase accounting adjustments in relation to Adjusted Transformation Services Revenue or True Health premiums revenue. The following table presents our reconciliation of segments total Adjusted EBITDA to net income (loss) attributable to Evolent Health, Inc. (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Net Income (Loss) Attributable to Evolent Health, Inc. $ (12,429 ) $ (12,588 ) $ (35,971 ) $ (47,506 ) Less: Interest income 968 411 2,918 813 Interest expense (853 ) (880 ) (2,561 ) (2,781 ) (Provision) benefit for income taxes (135 ) 1,714 (29 ) 2,009 Depreciation and amortization expenses (10,352 ) (7,717 ) (29,882 ) (21,236 ) Income (loss) from equity method investees (1,381 ) (369 ) (2,787 ) (1,446 ) Change in fair value of contingent consideration and indemnification asset (100 ) (100 ) 1,404 (300 ) Other income (expense), net (124 ) 15 (64 ) 21 Net (income) loss attributable to non-controlling interests 126 541 680 8,471 ASC 606 transition adjustments — — (4,498 ) — Purchase accounting adjustments (214 ) (449 ) (647 ) (1,224 ) Stock-based compensation expense (4,047 ) (5,708 ) (12,560 ) (16,172 ) Severance costs — — (1,489 ) — Amortization of contract cost assets (658 ) — (1,797 ) — Transaction costs (456 ) (2,694 ) (2,254 ) (9,972 ) Adjusted EBITDA $ 4,797 $ 2,648 $ 17,595 $ (5,689 ) Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

True Health Claims Reserves

True Health Claims Reserves	9 Months Ended
	Sep. 30, 2018
Insurance [Abstract]
True Health Claims Reserves	True Health Claims Reserves Claims reserves for the True Health segment reflect estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period notwithstanding that we did not own NMHC’s commercial business prior to January 2, 2018. For more recent months, the Company expects to rely more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. For each reporting period, the Company compares key assumptions used to establish the claims reserves to actual experience. When actual experience differs from these assumptions, claims reserves are adjusted through current period shareholders' net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. Activity in claims reserves was as follows (in thousands): For the Nine Months Ended September 30, 2018 Incurred costs related to current period $ 52,169 Paid costs related to current period 41,831 Change during the period 10,338 Beginning balance — Ending balance $ 10,338

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following represents supplemental disclosure of non-cash investing and financing information (in thousands): For the Nine Months Ended September 30, 2018 2017 Accrued property and equipment purchases $ 501 $ 83 Increase to goodwill from measurement period adjustments related to business combinations 4 1,766 Decrease in accrued financing costs related to 2021 Notes — 196 Consideration for asset acquisitions or business combinations 500 — Settlement of escrow related to asset acquisition 2,519 — Settlement of indemnification asset 1,004 — Tax benefit related to Accordion intangible technology — 2,042 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges 25,334 168,883 Decrease in deferred tax liability as a result of securities offerings 908 12,992

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of New Century Health On October 1, 2018 , the Company completed its previously announced acquisition of New Century Health. The closing merger consideration, net of cash on hand and certain closing adjustments, was $221.6 million , based on the closing price of Evolent’s Class A common stock on the New York Stock Exchange on October 1, 2018 , and consisted of 3.1 million shares of Evolent Class B common stock, an equal number of Evolent Health LLC Class B units and $117.2 million in cash. The shares issued at closing represent 3.8% of the Company’s issued and outstanding Class A common stock and Class B common stock after the transaction. The purchase price of $221.6 million includes an earn-out potential of up to $20.0 million , payable in cash and Evolent Class B common stock, subject to the satisfaction of certain conditions related to the operating results of New Century Health in 2019. Shares to be issued in relation to the earn-out are limited to 1.0 million shares of Evolent’s Class B common stock, with full payment expected to be made during the first quarter of 2020. The shares at closing were, and the shares for the earn-out, if any, will be issued in transactions exempt from registration under the Securities Act of 1933, as amended. Convertible debt issuance In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2025 Notes were issued at par for net proceeds, excluding expenses, of $167.3 million . We incurred $5.2 million of debt issuance costs in connection with the 2025 Notes, which will be amortized to non-cash interest expense over the contractual term of the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018 , and the initial purchasers completed the exercise in full of their option to purchase an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018 . The Company loaned the net proceeds to Evolent Health LLC, which intends to use the net proceeds for working capital and other general corporate purposes. Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019 , at a rate equal to 1.50% per annum. The 2025 Notes will mature on October 15, 2025 , unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding April 15, 2025 , the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. On or after April 15, 2025 , until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate at any time irrespective of any conditions. The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the Indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s Class A common stock or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022 . The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022 , if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The Consolidated Balance Sheet at December 31, 2017 , has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2017 Form 10-K.
Accounting Estimates and Assumptions	Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets, liabilities, consideration related to business combinations and asset acquisitions, revenue recognition including variable consideration, discounts and credits, estimated selling prices for performance obligations in contracts with multiple performance obligations, claims reserves, contingent payments, allowance for doubtful accounts, depreciable lives of assets, impairment of long lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and the useful lives of intangible assets.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation.
Operating Segments	Operating Segments Operating segments are defined as components of a business that earn revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of our technology-enabled services platform that supports our various value-based operations, such as delivery network alignment, population health performance, integrated cost and revenue management solutions and financial and administrative management services. Our True Health segment consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. See Note 17 for a discussion of our operating results by segment.
Revenue Recognition	Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. See “Changes in Accounting Principles” below for our updated revenue recognition policy as a result of our adoption of Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as short-term deferred revenue on our Consolidated Balance Sheets. Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-Step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition on our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Transformation Services Revenue Transformation services consist of strategic assessments, or Blueprint contracts, and implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Platform and Operations Services Revenue Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers. Generally we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically include a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue for platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.
Restricted Cash and Restricted Investments	Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations
Intangible Assets, Net	Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The Company acquired additional intangible assets in conjunction with a strategic acquisition made during 2018. Information regarding the determination and allocation of the fair value of the acquired assets and liabilities is further described within Note 4 . The following summarizes the estimated useful lives by asset classification: Corporate trade name 20 years Customer relationships 15-25 years Technology 5 years Provider network contracts 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 7 for additional discussion regarding our intangible assets.
Goodwill	Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. Goodwill is assigned to the reporting unit that benefits from the synergies arising from each business combination.
Foreign Currency	Foreign Currency The Company established an international subsidiary during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and average rates of exchange for revenue, costs, and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity.
Adoption of New Accounting Standards and Future Adoption of New Accounting Standards	Adoption of New Accounting Standards In June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting . The update expands the scope of ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU specifies that ASC 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments in the update also clarify that ASC 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. The update is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. We adopted the requirements of this standard effective July 1, 2018, and there was no impact to our financial condition and results of operations for the three and nine months ended September 30, 2018 . Going forward, we do not expect the adoption to have a material impact on our financial condition or results of operations. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , in order to clarify the principles of recognizing revenue. This standard establishes the core principle of recognizing revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB defines a five-step process that systematically identifies the various components of the revenue recognition process, culminating with the recognition of revenue upon satisfaction of an entity’s performance obligations. By completing all five steps of the process, the core principles of revenue recognition will be achieved. The new revenue standard (including updates) is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The guidance permits two methods of adoption: i) the full retrospective method applying the standard to each prior reporting period presented, or ii) the modified retrospective method with a cumulative effect of initially applying the guidance recognized at the date of initial application. The standard also allows entities to apply certain practical expedients at their discretion. The Company adopted the standard effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (“ASC 605”). The adoption of this standard resulted in changes related to revenue recognition for contracts that contain certain features, such as variable consideration. These changes generally accelerate revenue recognition. In addition, certain customer setup costs, which have historically been expensed as incurred, will now be capitalized. Evolent recognized the cumulative effect of applying the new revenue standard as a $17.3 million adjustment to the opening balance of retained earnings, including non-controlling interests, in the first quarter of 2018, primarily as a result of capitalization of expenses related to contract acquisition and fulfillment costs and acceleration of revenue due to variable consideration estimation. See Note 5 for additional disclosures regarding Evolent's contracts with customers. See Note 2 for updated revenue recognition accounting policy and the impact of adopting the new revenue recognition standard on Evolent’s financial statements. Future Adoption of New Accounting Standards In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customers Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact of adoption on our financial condition and results of operations. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We intend to adopt the requirements of this standard effective January 1, 2020, and are currently evaluating the impact of the adoption on our financial condition and results of operations. In February 2016, the FASB issued ASU 2016-02, Leases , which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight‑line basis over the term of the lease, respectively. A lessee is also required to record a right‑of‑use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (ASC Topic 842) supersedes the previous leases standard, ASC 840, Leases . The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has formulated an implementation team that is currently engaged in the evaluation process. We intend to adopt the requirements of this standard effective January 1, 2019, using a modified retrospective approach. We expect to take advantage of the package of practical expedients permitted within the new standard. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. Pursuant to ASU 2018-11, the Company will apply the new standard at its adoption date rather than at the earliest comparative period presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of retaining earnings. We anticipate that this standard will result in a material increase in the assets and liabilities on our consolidated balance sheets; however, we do not believe adoption will have a material impact on our results of operations.
Fair Value Measurements and Other Fair Value Disclosures	Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. See Notes 4 , 5 , 6 , 7 and 13 for further discussion of assets measured at fair value on a nonrecurring basis. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 8 for information regarding the fair value of the 2021 Notes.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of restricted cash and cash equivalents	Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: As of As of September 30, December 31, 2018 2017 Collateral for letters of credit for facility leases (1) $ 3,710 $ 3,812 Collateral with financial institutions (2) 22,028 24,725 Claims processing services (3) 8,942 26,286 Collateral for reinsurance agreement (4) 10,000 10,000 Other 1,042 862 Total restricted cash and restricted investments 45,722 65,685 Current restricted investments — 8,150 Current restricted cash 42,328 54,248 Total current restricted cash and restricted investments 42,328 62,398 Noncurrent restricted investments 712 605 Noncurrent restricted cash 2,682 2,682 Total noncurrent restricted cash and restricted investments $ 3,394 $ 3,287 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 9 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing arrangements. As of September 30, 2018 , and December 31, 2017 , approximately $22.0 million and $16.6 million of the collateral amount was in a trust account and invested in a money market fund. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 15 for further discussion of our fair value measurement. As of December 31, 2017 , approximately $8.2 million of the collateral amount was invested in restricted certificates of deposit with remaining maturities of less than 12 months. The restricted investments are classified as held-to-maturity and stated at amortized cost. Fair value of the certificates of deposit is determined using Level 2 inputs and approximates amortized cost as of December 31, 2017 . See Note 9 for further discussion of our risk-sharing arrangements. (3) Represents cash held by Evolent on behalf of partners for claims processing services. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. (4) Represents restricted cash required as part of our capital only reinsurance agreement to provide balance sheet support to NMHC. There is no transfer of underwriting risk to Evolent and we are not at risk for any cash payments on behalf of NMHC as part of the agreement. The reinsurance agreement is further discussed in Note 9 . As of September 30, 2018 , the full $10.0 million amount was invested in a money market fund. The amount invested in the money market fund is considered restricted cash and is carried at fair value, which approximates cost. As of December 31, 2017 , the full $10.0 million amount was held in a FDIC participating bank account. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. As of September 30, As of December 31, 2018 2017 2017 2016 Cash and cash equivalents $ 221,837 $ 287,143 $ 238,433 $ 134,563 Restricted cash and restricted investments 45,722 16,932 65,685 40,416 Restricted investments included in restricted cash and restricted investments (712 ) (8,150 ) (8,755 ) (4,950 ) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 266,847 $ 295,925 $ 295,363 $ 170,029
Schedule of intangible assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 20 years Customer relationships 15-25 years Technology 5 years Provider network contracts 5 years Details of our intangible assets (in thousands) are presented below: As of September 30, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 16.7 $ 19,000 $ 3,166 $ 15,834 Customer relationships (1) 19.5 208,719 25,550 183,169 Technology 2.4 55,933 27,264 28,669 Below market lease, net 4.3 4,097 2,918 1,179 Provider network contracts 4.3 2,300 345 1,955 Total $ 290,049 $ 59,243 $ 230,806 (1) The increase in the gross carrying amount of the customer relationships intangible is attributable to $2.7 million of acquired customer relationships from the NMHC transaction and $2.5 million related the Vestica Healthcare LLC (“Vestica”) transaction. The Company acquired certain assets from Vestica in March 2016. The transaction included additional consideration of up to $4.0 million , which was being held in escrow and was recorded within “Prepaid expenses and other noncurrent assets” on our Consolidated Balance Sheets. In February 2018, the Company and Vestica reached an agreement to settle $3.5 million of the $4.0 million in escrow. Based on the terms of the settlement agreement, the Company reclassified the unamortized portion of the additional consideration from “Prepaid expenses and other noncurrent assets” into “Customer relationships” as of the settlement date. See Note 4 for further information about the NMHC transaction and see “ Part II - Item 8. Financial Statements and Supplementary Data - Note 4 ” of our 2017 Form 10-K for further information about the Vestica transaction. As of December 31, 2017 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 17.4 $ 19,000 $ 2,454 $ 16,546 Customer relationships 20.5 203,500 18,312 185,188 Technology 3.1 55,802 17,810 37,992 Below market lease, net 4.8 4,197 2,662 1,535 Total $ 282,499 $ 41,238 $ 241,261
Schedule of adoption of ASC 606	In accordance with the requirements under ASU 2014-09, the impact of adoption to our consolidated financial statements was as follows. See Note 5 for additional disclosures regarding Evolent's contracts with customers. Condensed Consolidated Statements of Operations (unaudited, in thousands) For the Three Months Ended September 30, 2018 Amounts without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Revenue Transformation services $ 9,230 $ 9,556 $ (326 ) Platform and operations services 118,094 117,942 152 Expenses Cost of revenue (exclusive of depreciation and amortization presented separately below) 73,967 77,409 (3,442 ) Selling, general and administrative expenses 59,566 59,676 (110 ) Income (loss) before income taxes and non-controlling interests (12,420 ) (15,798 ) 3,378 For the Nine Months Ended September 30, 2018 Amounts without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Revenue Transformation services $ 23,950 $ 25,272 $ (1,322 ) Platform and operations services 341,258 339,485 1,773 Expenses Cost of revenue (exclusive of depreciation and amortization presented separately below) 214,945 218,786 (3,841 ) Selling, general and administrative expenses 172,495 173,644 (1,149 ) Income (loss) before income taxes and non-controlling interests (36,622 ) (42,063 ) 5,441 Condensed Consolidated Balance Sheets (unaudited, in thousands) As of September 30, 2018 Balances without Impact of adoption of adoption As Reported ASC 606 Higher/(Lower) Assets Accounts receivable, net $ 60,054 $ 57,848 $ 2,206 Contract assets (current) 3,705 — 3,705 Contract assets (noncurrent) 1,000 — 1,000 Contract cost assets 14,252 — 14,252 Liabilities and Shareholders' Equity (Deficit) Liabilities Deferred revenue $ 22,360 $ 24,100 $ (1,740 ) Other long-term liabilities 10,885 10,746 139 Shareholders' Equity (Deficit) Retained earnings (accumulated deficit) 66,696 44,580 22,116 Non-controlling interests 10,008 9,361 647 The following table summarizes the impact of the change in accounting principle to the Company’s Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 (in thousands): For the Nine Months Ended September 30, 2017 As Reported Adjustments As Adjusted Cash Flows from Investing Activities Purchases and maturities of restricted investments $ — $ (3,200 ) $ (3,200 ) Change in restricted cash and restricted investments (2,164 ) 2,164 — Net cash and restricted cash provided by (used in) investing activities 17,003 (1,036 ) 15,967 Cash Flows from Financing Activities Change in restricted cash held on behalf of partners for claims processing — (25,648 ) (25,648 ) Net cash and restricted cash provided by (used in) financing activities 169,570 (25,648 ) 143,922 Net increase (decrease) in cash and cash equivalents and restricted cash 152,580 (26,684 ) 125,896 Cash and cash equivalents and restricted cash as of beginning-of-period 134,563 35,466 170,029 Cash and cash equivalents and restricted cash as of end-of-period $ 287,143 $ 8,782 $ 295,925

Transactions (Tables)

Transactions (Tables)	9 Months Ended
	Sep. 30, 2018
Organizational Transactions [Abstract]
Schedule of net assets acquired	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 2, 2018 , as follows (in thousands): Purchase consideration Cash paid to NMHC $ 10,000 Cash paid to escrow agent 252 Total consideration $ 10,252 Identifiable intangible assets acquired and liabilities assumed Customer relationships $ 2,700 Provider network contracts 2,300 Above market lease (100 ) Accrued compensation and employee benefits (474 ) Goodwill 5,826 Net assets acquired $ 10,252
Business acquisition, pro forma information	The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands, except per share data). For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Revenue $ 149,947 $ 129,820 $ 433,959 $ 378,801 Net income (loss) (12,555 ) (11,320 ) (36,651 ) (65,113 ) Net income (loss) attributable to non-controlling interests (126 ) (413 ) (680 ) (8,414 ) Net income (loss) attributable to Evolent Health, Inc. (12,429 ) (10,907 ) (35,971 ) (56,699 ) Net income (loss) per Common Share available to common shareholders Basic $ (0.16 ) $ (0.16 ) $ (0.47 ) $ (0.93 ) Diluted (0.16 ) (0.16 ) (0.47 ) (0.93 )

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table represents Evolent’s Services segment revenue disaggregated by revenue type for the three and nine months ended September 30, 2018 (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2018 Services Revenue Transformation services $ 9,230 $ 23,950 Platform and operations services 116,226 335,509
Contract with customer, asset and liability	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): As of As of September 30, January 1, 2018 2018 Short-term receivables (1) $ 58,190 $ 47,131 Long-term receivables (1) 6,550 — Short-term contract assets 3,705 3,710 Long-term contract assets 1,000 1,791 Short-term deferred revenue 22,360 26,147 Long-term deferred revenue 1,000 493 (1) Excludes pharmacy claims receivable and premiums receivable

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Summary of property and equipment	The following summarizes our property and equipment (in thousands): As of As of September 30, December 31, 2018 2017 Computer hardware $ 8,602 $ 5,667 Furniture and equipment 3,038 2,448 Internal-use software development costs 73,679 48,557 Leasehold improvements 9,638 8,708 Total property and equipment 94,957 65,380 Accumulated depreciation and amortization (26,265 ) (14,458 ) Total property and equipment, net $ 68,692 $ 50,922

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The following tables summarize the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Nine Months Ended September 30, 2018 Services True Health Consolidated Balance as of beginning-of-period (1) $ 628,186 $ — $ 628,186 Goodwill Acquired (2) 1,234 5,826 7,060 Measurement period adjustments (2) 4 — 4 Foreign currency translation (2) (162 ) — (162 ) Balance as of end-of-period $ 629,262 $ 5,826 $ 635,088 (1) Net of cumulative inception to date impairment of $160.6 million . (2) Goodwill acquired, measurement period adjustments and foreign currency translation are all related to transactions completed during the first quarter of 2018. For the Year Ended December 31, 2017 (1) Balance as of beginning-of-period (2) $ 626,569 Measurement period adjustments (3) 1,617 Balance as of end-of-period $ 628,186 (1) All of the goodwill was allocated to the Services segment as of December 31, 2017, as the True Health segment was not established until the first quarter of 2018. (2) Net of cumulative inception to date impairment of $160.6 million . (3) Represents measurement period adjustments related to Valence Health and Aldera. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 4” in our 2017 Form 10-K for further information regarding the Valence Health and Aldera transactions.
Schedule of intangible assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 20 years Customer relationships 15-25 years Technology 5 years Provider network contracts 5 years Details of our intangible assets (in thousands) are presented below: As of September 30, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 16.7 $ 19,000 $ 3,166 $ 15,834 Customer relationships (1) 19.5 208,719 25,550 183,169 Technology 2.4 55,933 27,264 28,669 Below market lease, net 4.3 4,097 2,918 1,179 Provider network contracts 4.3 2,300 345 1,955 Total $ 290,049 $ 59,243 $ 230,806 (1) The increase in the gross carrying amount of the customer relationships intangible is attributable to $2.7 million of acquired customer relationships from the NMHC transaction and $2.5 million related the Vestica Healthcare LLC (“Vestica”) transaction. The Company acquired certain assets from Vestica in March 2016. The transaction included additional consideration of up to $4.0 million , which was being held in escrow and was recorded within “Prepaid expenses and other noncurrent assets” on our Consolidated Balance Sheets. In February 2018, the Company and Vestica reached an agreement to settle $3.5 million of the $4.0 million in escrow. Based on the terms of the settlement agreement, the Company reclassified the unamortized portion of the additional consideration from “Prepaid expenses and other noncurrent assets” into “Customer relationships” as of the settlement date. See Note 4 for further information about the NMHC transaction and see “ Part II - Item 8. Financial Statements and Supplementary Data - Note 4 ” of our 2017 Form 10-K for further information about the Vestica transaction. As of December 31, 2017 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 17.4 $ 19,000 $ 2,454 $ 16,546 Customer relationships 20.5 203,500 18,312 185,188 Technology 3.1 55,802 17,810 37,992 Below market lease, net 4.8 4,197 2,662 1,535 Total $ 282,499 $ 41,238 $ 241,261

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of convertible debt	The following table summarizes the carrying value of the long-term debt (in thousands): As of As of September 30, December 31, 2018 2017 Carrying value $ 122,082 $ 121,394 Unamortized discount 2,918 3,606 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 3.2 3.9

Commitments and Contingencies

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of major partners	The following table summarizes those partners who represented at least 10.0% of our revenue for the periods presented: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Customer A 18.8 % 19.0 % 18.9 % 18.5 % Customer B * * * 10.0 % * Represents less than 10.0% of the respective balance The following table summarizes those partners who represented at least 10.0% of our trade accounts receivable for the periods presented: As of As of September 30, December 31, 2018 2017 Customer B * 11.8 % Customer C 16.2 % 32.1 % Customer D * 16.5 % * Represents less than 10.0% of the respective balance

Earnings (Loss) Per Common Sh_2

Earnings (Loss) Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Computation of basic and diluted earnings per share	The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Net income (loss) $ (12,555 ) $ (13,129 ) $ (36,651 ) $ (55,977 ) Less: Net income (loss) attributable to non-controlling interests (126 ) (541 ) (680 ) (8,471 ) Net income (loss) available for common shareholders (1) (2) $ (12,429 ) $ (12,588 ) $ (35,971 ) $ (47,506 ) Weighted-average common shares outstanding (2) (3) 77,999 70,328 76,871 60,867 Earnings (Loss) per Common Share Basic $ (0.16 ) $ (0.18 ) $ (0.47 ) $ (0.78 ) Diluted (0.16 ) (0.18 ) (0.47 ) (0.78 ) (1) For periods of net loss, net income (loss) available for common shareholders is the same for both basic and diluted purposes. (2) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share. (3) For periods of net loss, shares used in the earnings (loss) per common share calculation represent basic shares as using diluted shares would be anti-dilutive.
Schedule of antidilutive securities excluded from computation of earnings per share	Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Exchangeable Class B common stock 766 2,654 1,251 8,846 Restricted stock units ("RSUs") 1,197 577 923 557 Stock options and performance-based stock options 2,698 2,976 2,486 3,031 Convertible senior notes 5,201 5,201 5,201 5,201 Total 9,862 11,408 9,861 17,635

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense	Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Award Type Stock options $ 2,139 $ 4,291 $ 7,009 $ 12,452 Performance-based stock options 113 113 334 335 RSUs 1,795 1,304 5,217 3,385 Total $ 4,047 $ 5,708 $ 12,560 $ 16,172 Line Item Cost of revenue $ 376 $ 401 $ 1,130 $ 1,143 Selling, general and administrative expenses 3,671 5,307 11,430 15,029 Total $ 4,047 $ 5,708 $ 12,560 $ 16,172
Stock-based awards granted	Stock-based awards were granted as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Stock options 3 84 1,054 961 RSUs 18 37 857 461

Non-controlling Interests (Tabl

Non-controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2018
Noncontrolling Interest [Abstract]
Schedule of changes in non-controlling interests	Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Non-controlling interests as of beginning-of-period $ 10,148 $ 34,680 $ 35,427 $ 209,588 Cumulative-effect adjustment from adoption of new accounting principle — — 594 — Decrease in non-controlling interests as a result of Class B Exchanges — — (25,334 ) (168,883 ) Reclassification of non-controlling interests (14 ) 1,793 1 3,698 Net income (loss) attributable to non-controlling interests (126 ) (541 ) (680 ) (8,471 ) Non-controlling interests as of end-of-period $ 10,008 $ 35,932 $ 10,008 $ 35,932

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Summary of assets at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 41,186 $ — $ — $ 41,186 Restricted cash and restricted investments (1) 32,028 — — 32,028 Total $ 73,214 $ — $ — $ 73,214 Liabilities Contingent consideration (2) — — 8,300 8,300 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 60,535 $ — $ — $ 60,535 Restricted cash and restricted investments (1) 16,575 — — 16,575 Total $ 77,110 $ — $ — $ 77,110 Liabilities Contingent consideration (2) — — 8,700 8,700 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of September 30, 2018 , and December 31, 2017 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition as described below.
Summary of liabilities at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 41,186 $ — $ — $ 41,186 Restricted cash and restricted investments (1) 32,028 — — 32,028 Total $ 73,214 $ — $ — $ 73,214 Liabilities Contingent consideration (2) — — 8,300 8,300 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 60,535 $ — $ — $ 60,535 Restricted cash and restricted investments (1) 16,575 — — 16,575 Total $ 77,110 $ — $ — $ 77,110 Liabilities Contingent consideration (2) — — 8,700 8,700 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of September 30, 2018 , and December 31, 2017 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition as described below.
Changes in contingent consideration measured at fair value	The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Balance as of beginning-of-period $ 8,200 $ 8,500 $ 8,700 $ 8,300 Realized and unrealized (gains) losses, net 100 100 (400 ) 300 Balance as of end-of-period $ 8,300 $ 8,600 $ 8,300 $ 8,600
Valuation techniques and significant unobservable inputs of Level 3 fair value measurements	The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: As of September 30, 2018 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration (1) $ 8,300 Real options approach Risk-adjusted recurring revenue CAGR 112.7 % (2) Discount rate/time value 3.8% - 4.5% (1) Related to additional Passport earn-out consideration as described above. (2) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rate is based on a theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR over the period 2019-2021 is 78.6% . As of December 31, 2017 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration (1) $ 8,700 Real options approach Risk-adjusted recurring revenue CAGR 92.5 % (2) Discount rate/time value 2.7% - 4.0% (1) Related to additional Passport earn-out consideration as described above. (2) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rate is based on a theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR over the period 2019-2021 is 19.2% .

Related Parties (Tables)

Related Parties (Tables)	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Revenues and expenses related to affiliates	The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Revenue Transformation services $ 5,332 $ 352 $ 6,112 $ 597 Platform and operations services 12,180 9,411 27,072 24,764 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 2,390 5,299 6,842 17,382 Selling, general and administrative expenses 241 514 620 1,038

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Reconciliation of revenue from segments to consolidated	The following tables present our segment information (in thousands): Intersegment Services True Health (1) Eliminations Consolidated Adjusted Revenue Three Months Ended September 30, 2018 Services: Adjusted Transformation Services $ 9,230 $ — $ — $ 9,230 Adjusted Platform and Operations Services 121,845 — (3,537 ) 118,308 Adjusted Services Revenue 131,075 — (3,537 ) 127,538 True Health: Premiums — 22,829 (206 ) 22,623 Adjusted Revenue 131,075 22,829 (3,743 ) 150,161 Purchase accounting adjustments (2) (214 ) — — (214 ) Total revenue $ 130,861 $ 22,829 $ (3,743 ) $ 149,947 Three Months Ended September 30, 2017 Services: Adjusted Transformation Services $ 8,204 $ — $ — $ 8,204 Adjusted Platform and Operations Services 100,157 — — 100,157 Adjusted Services Revenue 108,361 — — 108,361 Adjusted Revenue 108,361 — — 108,361 Purchase accounting adjustments (2) (449 ) — — (449 ) Total revenue $ 107,912 $ — $ — $ 107,912 Segments Services True Health (1) Total Three Months Ended September 30, 2018 Adjusted EBITDA $ 4,065 $ 732 $ 4,797 Three Months Ended September 30, 2017 Adjusted EBITDA $ 2,648 $ — $ 2,648 (1) The True Health segment was created in January 2018. (2) Purchase accounting adjustments pertain to Adjusted Platform and Operations Services Revenue. There were no purchase accounting adjustments in relation to Adjusted Transformation Services Revenue or True Health premiums revenue. Intersegment Services True Health (1) Eliminations Consolidated Adjusted Revenue Nine Months Ended September 30, 2018 Services: Adjusted Transformation Services $ 27,605 $ — $ — $ 27,605 Adjusted Platform and Operations Services 353,697 — (10,949 ) 342,748 Adjusted Services Revenue 381,302 — (10,949 ) 370,353 True Health: Premiums — 69,353 (602 ) 68,751 Adjusted Revenue 381,302 69,353 (11,551 ) 439,104 ASC 606 transition adjustment (2) (4,498 ) — — (4,498 ) Purchase accounting adjustments (3) (647 ) — — (647 ) Total revenue $ 376,157 $ 69,353 $ (11,551 ) $ 433,959 Nine Months Ended September 30, 2017 Services: Adjusted Transformation Services $ 23,799 $ — $ — $ 23,799 Adjusted Platform and Operations Services 298,646 — — 298,646 Adjusted Services Revenue 322,445 — — 322,445 Adjusted Revenue 322,445 — — 322,445 Purchase accounting adjustments (3) (1,224 ) — — (1,224 ) Total revenue $ 321,221 $ — $ — $ 321,221 Segments Services True Health (1) Total Nine Months Ended September 30, 2018 Adjusted EBITDA $ 16,674 $ 921 $ 17,595 Nine Months Ended September 30, 2017 Adjusted EBITDA $ (5,689 ) $ — $ (5,689 ) (1) The True Health segment was created in January 2018. (2) Adjustment to Adjusted Transformation Services Revenue was approximately $3.7 million and the adjustment to Adjusted Platform and Operations Services Revenue was approximately $0.8 million . (3) Purchase accounting adjustments pertain to Adjusted Platform and Operations Services Revenue. There were no purchase accounting adjustments in relation to Adjusted Transformation Services Revenue or True Health premiums revenue.
Reconciliation of Adjusted EBITDA to net income (loss)	The following table presents our reconciliation of segments total Adjusted EBITDA to net income (loss) attributable to Evolent Health, Inc. (in thousands): For the Three For the Nine Months Ended Months Ended September 30, September 30, 2018 2017 2018 2017 Net Income (Loss) Attributable to Evolent Health, Inc. $ (12,429 ) $ (12,588 ) $ (35,971 ) $ (47,506 ) Less: Interest income 968 411 2,918 813 Interest expense (853 ) (880 ) (2,561 ) (2,781 ) (Provision) benefit for income taxes (135 ) 1,714 (29 ) 2,009 Depreciation and amortization expenses (10,352 ) (7,717 ) (29,882 ) (21,236 ) Income (loss) from equity method investees (1,381 ) (369 ) (2,787 ) (1,446 ) Change in fair value of contingent consideration and indemnification asset (100 ) (100 ) 1,404 (300 ) Other income (expense), net (124 ) 15 (64 ) 21 Net (income) loss attributable to non-controlling interests 126 541 680 8,471 ASC 606 transition adjustments — — (4,498 ) — Purchase accounting adjustments (214 ) (449 ) (647 ) (1,224 ) Stock-based compensation expense (4,047 ) (5,708 ) (12,560 ) (16,172 ) Severance costs — — (1,489 ) — Amortization of contract cost assets (658 ) — (1,797 ) — Transaction costs (456 ) (2,694 ) (2,254 ) (9,972 ) Adjusted EBITDA $ 4,797 $ 2,648 $ 17,595 $ (5,689 )

True Health Claims Reserves (Ta

True Health Claims Reserves (Tables)	9 Months Ended
	Sep. 30, 2018
Insurance [Abstract]
Activity in claims reserves	Activity in claims reserves was as follows (in thousands): For the Nine Months Ended September 30, 2018 Incurred costs related to current period $ 52,169 Paid costs related to current period 41,831 Change during the period 10,338 Beginning balance — Ending balance $ 10,338

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Supplemental cash flow information	The following represents supplemental disclosure of non-cash investing and financing information (in thousands): For the Nine Months Ended September 30, 2018 2017 Accrued property and equipment purchases $ 501 $ 83 Increase to goodwill from measurement period adjustments related to business combinations 4 1,766 Decrease in accrued financing costs related to 2021 Notes — 196 Consideration for asset acquisitions or business combinations 500 — Settlement of escrow related to asset acquisition 2,519 — Settlement of indemnification asset 1,004 — Tax benefit related to Accordion intangible technology — 2,042 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges 25,334 168,883 Decrease in deferred tax liability as a result of securities offerings 908 12,992

Organization (Details)

Organization (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)segment	Mar. 31, 2018	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Aug. 31, 2017	Jul. 31, 2017	Jun. 30, 2017	May 31, 2017	Apr. 30, 2017	Mar. 31, 2017	Feb. 28, 2017	Dec. 31, 2016USD ($)	Jun. 05, 2015
Organization [Line Items]
Number of reportable segments | segment	2
Cash and cash equivalents | $	$ 221,837		$ 238,433	$ 287,143								$ 134,563
Evolent Health LLC
Organization [Line Items]
Parent's ownership percentage	99.00%	98.90%	96.60%		96.60%	96.10%	96.10%	90.50%	84.90%	83.90%	77.40%		70.30%
Evolent Health LLC | Pre-Organization Members
Organization [Line Items]
Evolent Health LLC ownership interest	100.00%

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)segment	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Accounting Policies [Abstract]
Number of reportable segments | segment	2
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	$ 45,722	$ 65,685	$ 16,932	$ 40,416
Current restricted investments	0	8,150
Current restricted cash	42,328	54,248
Total current restricted cash and restricted investments	42,328	62,398
Noncurrent restricted investments	712	605
Noncurrent restricted cash	2,682	2,682
Total non-current restricted cash and restricted investments	3,394	3,287
Cash and cash equivalents	221,837	238,433	287,143	134,563
Restricted investments included in restricted cash and restricted investments	(712)	(8,755)	$ (8,150)	$ (4,950)
Cash and cash equivalents and restricted cash as of end-of-period	266,847
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	3,710	3,812
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	22,028	24,725
Claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	8,942	26,286
Collateral for reinsurance agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	10,000	10,000
Other
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	1,042	862
Collateral with financial institutions, money market fund
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		16,600
Money market funds
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	$ 10,000
FDIC participating bank account
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		$ 10,000

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles - Notes Receivable (Details)	12 Months Ended
	Dec. 31, 2017USD ($)installment	Sep. 30, 2018USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 20,000,000	$ 6,000,000
Loans Payable | Implementation Fund Loan | Current Customer
Accounts, Notes, Loans and Financing Receivable [Line Items]
Face amount	$ 20,000,000
Interest rate	2.50%
Number of equal principal and interest installments | installment	10
Amount of equal principal and interest installments	$ 2,000,000
Notes receivable	20,000,000	6,000,000
Accrued interest	$ 100,000	$ 100,000

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles - Intangible Assets, Net (Details)	9 Months Ended
	Sep. 30, 2018
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	15 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	25 years
Technology
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

Basis of Presentation, Summar_7

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles - Foreign Currency (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Accounting Policies [Abstract]
Foreign currency translation adjustment	$ (116)	$ 0	$ (264)	$ 0
Accumulated other comprehensive income (loss)	$ (264)		$ (264)		$ 0

Basis of Presentation, Summar_8

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles - Change in Accounting Principle (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue
Revenues		$ 149,947	$ 107,912	$ 433,959	$ 321,221
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)	[1]	73,967	68,281	214,945	203,804
Selling, general and administrative expenses	[1]	59,566	45,834	172,495	150,474
Income (loss) before income taxes and non-controlling interests		(12,420)	(14,843)	(36,622)	(57,986)
ASSETS
Accounts receivable, net		60,054		60,054			$ 48,947
Contract assets (current)		3,705		3,705		$ 3,710	0
Contract assets (noncurrent)		1,000		1,000		1,791	0
Contract cost assets		14,252		14,252			0
Liabilities
Deferred revenue		22,360		22,360		$ 26,147	24,807
Other long-term liabilities		10,885		10,885			9,861
Shareholders' Equity (Deficit)
Retained earnings (accumulated deficit)		66,696		66,696			85,952
Non-controlling interests		10,008		10,008			$ 35,427
Balances without adoption of ASC 606
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)		77,409		218,786
Selling, general and administrative expenses		59,676		173,644
Income (loss) before income taxes and non-controlling interests		(15,798)		(42,063)
ASSETS
Accounts receivable, net		57,848		57,848
Contract assets (current)		0		0
Contract assets (noncurrent)		0		0
Contract cost assets		0		0
Liabilities
Deferred revenue		24,100		24,100
Other long-term liabilities		10,746		10,746
Shareholders' Equity (Deficit)
Retained earnings (accumulated deficit)		44,580		44,580
Non-controlling interests		9,361		9,361
Impact of adoption Higher/(Lower)
Revenue
Revenues		(214)	(449)	(647)	(1,224)
Impact of adoption Higher/(Lower) | Accounting Standards Update 2014-09
Revenue
Revenues				(4,498)
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)		(3,442)		(3,841)
Selling, general and administrative expenses		(110)		(1,149)
Income (loss) before income taxes and non-controlling interests		3,378		5,441
ASSETS
Accounts receivable, net		2,206		2,206
Contract assets (current)		3,705		3,705
Contract assets (noncurrent)		1,000		1,000
Contract cost assets		14,252		14,252
Liabilities
Deferred revenue		(1,740)		(1,740)
Other long-term liabilities		139		139
Shareholders' Equity (Deficit)
Retained earnings (accumulated deficit)		22,116		22,116
Non-controlling interests		647		647
Transformation services
Revenue
Revenues	[1]	9,230	8,204	23,950	23,799
Transformation services | Balances without adoption of ASC 606
Revenue
Revenues		9,556		25,272
Transformation services | Impact of adoption Higher/(Lower) | Accounting Standards Update 2014-09
Revenue
Revenues		(326)		(1,322)
Platform and operations services
Revenue
Revenues	[1]	118,094	$ 99,708	341,258	$ 297,422
Platform and operations services | Balances without adoption of ASC 606
Revenue
Revenues		117,942		339,485
Platform and operations services | Impact of adoption Higher/(Lower) | Accounting Standards Update 2014-09
Revenue
Revenues		$ 152		$ 1,773
[1]	See Note 16 for amounts related to affiliates included in these line items.

Basis of Presentation, Summar_9

Basis of Presentation, Summary of Significant Accounting Policies and Changes in Accounting Principles - Statement of Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Investing Activities
Purchases and maturities of restricted investments	$ (8,043)	$ 3,200
Net cash and restricted cash provided by (used in) investing activities	(24,933)	15,967
Cash Flows from Financing Activities
Change in restricted cash held on behalf of partners for claims processing	(17,344)	(25,648)
Net cash and restricted cash provided by (used in) financing activities	(7,935)	143,922
Net increase (decrease) in cash and cash equivalents and restricted cash	(28,516)	125,896
Cash and cash equivalents and restricted cash as of beginning-of-period	295,363	170,029
Cash and cash equivalents and restricted cash as of end-of-period	$ 266,847	295,925
Accounting Standards Update 2016-18
Cash Flows from Investing Activities
Purchases and maturities of restricted investments		(3,200)
Change in restricted cash and restricted investments		0
Net cash and restricted cash provided by (used in) investing activities		15,967
Cash Flows from Financing Activities
Change in restricted cash held on behalf of partners for claims processing		(25,648)
Net cash and restricted cash provided by (used in) financing activities		143,922
Net increase (decrease) in cash and cash equivalents and restricted cash		125,896
Cash and cash equivalents and restricted cash as of beginning-of-period		170,029
Cash and cash equivalents and restricted cash as of end-of-period		295,925
Accounting Standards Update 2016-18 | As Reported
Cash Flows from Investing Activities
Purchases and maturities of restricted investments		0
Change in restricted cash and restricted investments		(2,164)
Net cash and restricted cash provided by (used in) investing activities		17,003
Cash Flows from Financing Activities
Change in restricted cash held on behalf of partners for claims processing		0
Net cash and restricted cash provided by (used in) financing activities		169,570
Net increase (decrease) in cash and cash equivalents and restricted cash		152,580
Cash and cash equivalents and restricted cash as of beginning-of-period		134,563
Cash and cash equivalents and restricted cash as of end-of-period		287,143
Accounting Standards Update 2016-18 | Adjustments
Cash Flows from Investing Activities
Purchases and maturities of restricted investments		(3,200)
Change in restricted cash and restricted investments		2,164
Net cash and restricted cash provided by (used in) investing activities		(1,036)
Cash Flows from Financing Activities
Change in restricted cash held on behalf of partners for claims processing		(25,648)
Net cash and restricted cash provided by (used in) financing activities		(25,648)
Net increase (decrease) in cash and cash equivalents and restricted cash		(26,684)
Cash and cash equivalents and restricted cash as of beginning-of-period		35,466
Cash and cash equivalents and restricted cash as of end-of-period		$ 8,782

Recently Issued Accounting St_2

Recently Issued Accounting Standards (Details) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect on retained earnings	$ 17.3

Transactions - New Mexico Healt

Transactions - New Mexico Health Connections (Details) - USD ($) $ in Thousands	Jan. 02, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Purchase consideration:
Cash paid to NMHC		$ 11,552	$ 3,694
Identifiable intangible assets acquired and liabilities assumed
Goodwill		$ 635,088		$ 628,186	$ 626,569
Provider network contracts
Identifiable intangible assets acquired and liabilities assumed
Useful life		5 years
New Mexico Health Connections
Business Acquisition [Line Items]
Transaction costs				$ 1,200
Purchase consideration:
Cash paid to NMHC	$ 10,000
Cash paid to escrow agent	252
Total consideration	10,252
Identifiable intangible assets acquired and liabilities assumed
Accrued compensation and employee benefits	(474)
Goodwill	5,826
Net assets acquired	10,252
New Mexico Health Connections | Customer relationships
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets acquired and liabilities assumed	$ 2,700
Useful life	15 years
New Mexico Health Connections | Provider network contracts
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets acquired and liabilities assumed	$ 2,300
Useful life	5 years
New Mexico Health Connections | Above market lease
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets acquired and liabilities assumed	$ (100)

Transactions - Pro Forma Inform

Transactions - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Organizational Transactions [Abstract]
Revenue	$ 149,947	$ 129,820	$ 433,959	$ 378,801
Net income (loss)	(12,555)	(11,320)	(36,651)	(65,113)
Net income (loss) attributable to non-controlling interests	(126)	(413)	(680)	(8,414)
Net income (loss) attributable to Evolent Health, Inc.	$ (12,429)	$ (10,907)	$ (35,971)	$ (56,699)
Net income (loss) available to common shareholders, Basic (in dollars per share)	$ (0.16)	$ (0.16)	$ (0.47)	$ (0.93)
Net income (loss) available to common shareholders, Diluted (in dollars per share)	$ (0.16)	$ (0.16)	$ (0.47)	$ (0.93)

Transactions - Secondary Offeri

Transactions - Secondary Offerings and Sales (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended	6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2018	Aug. 31, 2017	Jun. 30, 2017	May 31, 2017	Mar. 31, 2017	Sep. 30, 2017	Aug. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 30, 2018	Jul. 31, 2017	Apr. 30, 2017	Feb. 28, 2017	Jun. 05, 2015
Business Acquisition [Line Items]
Proceeds from issuance of common stock								$ 0	$ 166,947
Payments of stock issuance costs						$ 300			$ 1,500
Evolent Health LLC
Business Acquisition [Line Items]
Parent's ownership percentage	98.90%	96.60%	96.10%	90.50%	83.90%		96.60%	99.00%		96.60%		96.10%	84.90%	77.40%	70.30%
Evolent Health LLC | Over-Allotment Option
Business Acquisition [Line Items]
Parent's ownership percentage					84.90%									83.90%
Class A
Business Acquisition [Line Items]
Issuance of common stock (in shares)										20,100,000
Common stock, outstanding (in shares)								78,392,052		74,723,597
Proceeds from issuance of common stock, net of payments of stock issuance costs		$ 166,900
Proceeds from issuance of common stock		$ 175,000
Class A | Investor Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)										12,600,000
Class A | Management Selling Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)										100,000
Class A | Evolent Health, Selling Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)										7,400,000
Class A | Common Stock
Business Acquisition [Line Items]
Issuance of common stock (in shares)	3,000,000	8,800,000	4,500,000	7,000,000	7,500,000		19,700,000			8,816,000
Share price (in usd per share)		$ 19.85	$ 25.87	$ 24.30	$ 19.53		$ 19.85
Payments of stock issuance costs		$ 8,100
Class A | Common Stock | Over-Allotment Option
Business Acquisition [Line Items]
Issuance of common stock (in shares)					1,100,000
Share price (in usd per share)					$ 19.53
Class A | Common Stock | Investor Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)	1,800,000		3,800,000	3,800,000	4,400,000
Common stock, outstanding (in shares)											0
Class A | Common Stock | Investor Stockholders | Over-Allotment Option
Business Acquisition [Line Items]
Issuance of common stock (in shares)					600,000
Class A | Common Stock | Underwriters
Business Acquisition [Line Items]
Share price (in usd per share)		$ 19.01					$ 19.01
Class A | Common Stock | Management Selling Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)				100,000
Class A | Common Stock | Evolent Health, Selling Stockholders
Business Acquisition [Line Items]
Issuance of common stock (in shares)	1,200,000		700,000	3,100,000	3,100,000
Class A | Common Stock | Evolent Health, Selling Stockholders | Over-Allotment Option
Business Acquisition [Line Items]
Issuance of common stock (in shares)					500,000

Transactions - Accordion Health

Transactions - Accordion Health, Inc. (Details) - Accordion $ in Millions	Jun. 08, 2017USD ($)
Business Acquisition [Line Items]
Accordion purchase agreement, amount	$ 3.2
Accordion purchase agreement, contingent earn-out	0.8
Accordion purchase agreement, deferred tax liabilities	2
Technology Assets
Business Acquisition [Line Items]
Accordion purchase agreement, intangible assets acquired	3.3
Accordion purchase agreement, capitalized transaction costs	$ 0.1
Intangible asset, useful life	5 years
Accordion purchase agreement, increase in intangible asset	$ 2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues		$ 149,947	$ 107,912	$ 433,959	$ 321,221
Transformation services
Disaggregation of Revenue [Line Items]
Revenues	[1]	9,230	8,204	23,950	23,799
Platform and operations services
Disaggregation of Revenue [Line Items]
Revenues	[1]	118,094	$ 99,708	341,258	$ 297,422
Services | Transformation services
Disaggregation of Revenue [Line Items]
Revenues		9,230		23,950
Services | Platform and operations services
Disaggregation of Revenue [Line Items]
Revenues		$ 116,226		$ 335,509
[1]	See Note 16 for amounts related to affiliates included in these line items.

Revenue Recognition - Transacti

Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions	Sep. 30, 2018USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation	$ 125
Revenue, remaining performance obligation, percent to be recognized in current fiscal year	60.00%
Revenue, remaining performance obligation, percent to be recognized in next fiscal year	84.00%

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue from Contract with Customer [Abstract]
Short-term receivables	$ 58,190	$ 58,190	$ 47,131
Long-term receivables	6,550	6,550	0
Short-term contract assets	3,705	3,705	3,710	$ 0
Long-term contract assets	1,000	1,000	1,791	0
Short-term deferred revenue	22,360	22,360	26,147	$ 24,807
Long-term deferred revenue	1,000	1,000	$ 493
Contract asset, reclassified to receivable		(800)
Deferred revenue increase		(3,300)
Deferred revenue, revenue recognized	3,700	17,000
Deferred revenue, adjustment due to net gain share, service-level agreement true-ups and changes in estimates	$ 9,400	$ 11,500

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Capitalized Contract Cost [Line Items]
Contract cost amortization		$ 1,900	$ 0
Capitalized contract cost, amortization period	5 years	5 years
Bonuses and Commissions
Capitalized Contract Cost [Line Items]
Contract cost assets	$ 2,000	$ 2,000
Contract cost amortization	100	200
Contract Fulfillment Costs
Capitalized Contract Cost [Line Items]
Contract cost assets	12,300	12,300
Contract cost amortization	$ 600	$ 1,700

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 94,957		$ 94,957		$ 65,380
Accumulated depreciation and amortization	(26,265)		(26,265)		(14,458)
Total property and equipment, net	68,692		68,692		50,922
Depreciation expense	4,300	$ 2,300	11,800	$ 6,000
Capitalized computer software, amortization	3,100	1,200	8,500	2,800
Computer hardware
Property, Plant and Equipment [Line Items]
Total property and equipment	8,602		8,602		5,667
Furniture and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3,038		3,038		2,448
Internal-use software development costs
Property, Plant and Equipment [Line Items]
Total property and equipment	73,679		73,679		48,557
Total property and equipment, net	58,700		58,700		42,100
Capitalized computer software additions	7,000	$ 8,400	25,100	$ 20,400
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 9,638		$ 9,638		$ 8,708

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Goodwill (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)reporting_unit	Dec. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of reporting units | reporting_unit	2
Goodwill [Roll Forward]
Balance as of beginning-of-period	$ 628,186	$ 626,569
Goodwill Acquired	7,060
Measurement period adjustment, goodwill	4	1,617
Foreign currency translation	(162)
Balance as of end-of-period	635,088	628,186
Accumulated impairment	160,600	160,600
Services
Goodwill [Roll Forward]
Balance as of beginning-of-period	628,186
Goodwill Acquired	1,234
Measurement period adjustment, goodwill	4
Foreign currency translation	(162)
Balance as of end-of-period	629,262	628,186
True Health
Goodwill [Roll Forward]
Balance as of beginning-of-period	0
Goodwill Acquired	5,826
Measurement period adjustment, goodwill	0
Foreign currency translation	0
Balance as of end-of-period	$ 5,826	$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jan. 02, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 290,049		$ 290,049		$ 282,499
Accumulated Amortization		59,243		59,243		41,238
Net Carrying Value		230,806		230,806		$ 241,261
Amortization of intangible assets		6,100	$ 5,300	$ 18,000	$ 15,000
Vestica
Finite-Lived Intangible Assets [Line Items]
Contingent consideration settled	$ 3,500
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life				16 years 8 months 15 days		17 years 4 months 26 days
Gross Carrying Amount		19,000		$ 19,000		$ 19,000
Accumulated Amortization		3,166		3,166		2,454
Net Carrying Value		15,834		$ 15,834		$ 16,546
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life				19 years 6 months		20 years 6 months
Gross Carrying Amount		208,719		$ 208,719		$ 203,500
Accumulated Amortization		25,550		25,550		18,312
Net Carrying Value		183,169		$ 183,169		$ 185,188
Customer relationships | New Mexico Health Connections
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets							$ 2,700
Customer relationships | Vestica
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets							2,500
Contingent consideration, asset, held in escrow							4,000
Technology
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life				2 years 5 months 5 days		3 years 1 month 12 days
Gross Carrying Amount		55,933		$ 55,933		$ 55,802
Accumulated Amortization		27,264		27,264		17,810
Net Carrying Value		28,669		$ 28,669		$ 37,992
Below market lease, net
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life				4 years 4 months		4 years 9 months 25 days
Gross Carrying Amount		4,097		$ 4,097		$ 4,197
Accumulated Amortization		2,918		2,918		2,662
Net Carrying Value		1,179		$ 1,179		$ 1,535
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life				4 years 4 months
Gross Carrying Amount		2,300		$ 2,300
Accumulated Amortization		345		345
Net Carrying Value		$ 1,955		$ 1,955
Provider network contracts | New Mexico Health Connections
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets							$ 2,300

Long-term Debt (Details)

Long-term Debt (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2016USD ($)shares$ / shares	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Amortization of deferred financing costs				$ 688,000	$ 685,000
Senior Notes | Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Face amount	$ 125,000,000	$ 125,000,000		$ 125,000,000		$ 125,000,000
Interest rate	2.00%
Proceeds from issuance of debt	$ 120,400,000
Debt issuance costs	$ 4,600,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Interest expense		600,000	$ 1,900,000
Amortization of deferred financing costs		$ 200,000	$ 700,000
Debt conversion denominator shares per principal amount	$ 1,000
Senior Notes | Convertible Senior Notes due 2021 | Class A | Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $1000 principal amount	0.0416082
Conversion price (in dollars per share) | $ / shares	$ 24.03
Initial conversion amount (in shares) | shares	5.2

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - Convertible Senior Notes due 2021 - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Jun. 27, 2018	Dec. 31, 2016
Debt Instrument [Line Items]
Carrying value	$ 122,082,000	$ 121,394,000
Unamortized discount	2,918,000	3,606,000
Principal amount	$ 125,000,000	$ 125,000,000		$ 125,000,000
Remaining amortization period	3 years 2 months 24 days	3 years 10 months 25 days
Level 2
Debt Instrument [Line Items]
Fair value		$ 120,400,000	$ 169,100,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) shares in Thousands	1 Months Ended					3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2018	Aug. 31, 2017	Jun. 30, 2017	May 31, 2017	Mar. 31, 2017	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Aug. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Tax receivables agreement, percent of tax savings to be paid						85.00%					85.00%
Operating capital support commitment, maximum amount						$ 2,600,000	$ 0				$ 2,600,000		$ 0
Rent expense						3,300,000		$ 3,000,000			10,100,000	$ 8,000,000
Restricted funds						45,722,000	$ 65,685,000	16,932,000			45,722,000	16,932,000	$ 65,685,000	$ 40,416,000
Payments of stock issuance costs								$ 300,000				$ 1,500,000
New Mexico Health Connections
Restricted Cash and Cash Equivalents Items [Line Items]
Reinsurance arrangement, term							15 months
Reinsurance arrangement, capital amount							$ 10,000,000
Reinsurance arrangement, quarterly fee							200,000
Class A
Restricted Cash and Cash Equivalents Items [Line Items]
Issuance of common stock (in shares)													20,100
Class A | Common Stock
Restricted Cash and Cash Equivalents Items [Line Items]
Issuance of common stock (in shares)	3,000	8,800	4,500	7,000	7,500					19,700			8,816
Payments of stock issuance costs		$ 8,100,000
Letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds						3,710,000	3,812,000				3,710,000		$ 3,812,000
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds						22,028,000	24,725,000				22,028,000		24,725,000
Collateral for reinsurance agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds						10,000,000	10,000,000				10,000,000		10,000,000
Collateral for reinsurance agreement | New Mexico Health Connections
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds							$ 10,000,000						$ 10,000,000
Minimum
Restricted Cash and Cash Equivalents Items [Line Items]
Letters of credit outstanding, minimum						$ 3,700,000					$ 3,700,000
Letter of Credit | Line of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Line of credit, maximum borrowing capacity					$ 5,000,000				$ 5,000,000
Line of credit, quarterly rental fee percentage									0.80%

Commitments and Contingencies_2

Commitments and Contingencies - Concentration Risk (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Concentration Risk [Line Items]
Percentage of cash and cash equivalents held with FDIC participating banks	72.30%		72.30%
Cash and cash equivalents (including restricted cash)	$ 266.8		$ 266.8
Percentage of cash and cash equivalents held in money market funds	27.40%		27.40%
Percentage of cash held in international banks (less than)	1.00%		1.00%
Customer B | Customer Concentration Risk | Accounts Receivable | Customer Receivable
Concentration Risk [Line Items]
Concentration risk					11.80%
Customer B | Customer Concentration Risk | Revenue
Concentration Risk [Line Items]
Concentration risk				10.00%
Customer C | Customer Concentration Risk | Accounts Receivable | Customer Receivable
Concentration Risk [Line Items]
Concentration risk			16.20%		32.10%
Customer D | Customer Concentration Risk | Accounts Receivable | Customer Receivable
Concentration Risk [Line Items]
Concentration risk					16.50%
Customer A | Customer Concentration Risk | Revenue
Concentration Risk [Line Items]
Concentration risk	18.80%	19.00%	18.90%	18.50%

Earnings (Loss) Per Common Sh_3

Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Earnings Per Share [Abstract]
Net income (loss)	$ (12,555)	$ (13,129)	$ (36,651)	$ (55,977)	$ (69,767)
Less:
Net income (loss) attributable to non-controlling interests	(126)	(541)	(680)	(8,471)
Net income (loss) available for common shareholders	$ (12,429)	$ (12,588)	$ (35,971)	$ (47,506)
Weighted-average common shares outstanding (in shares)	77,999,000	70,328,000	76,871,000	60,867,000
Earnings (Loss) per Common Share
Basic (in dollars per share)	$ (0.16)	$ (0.18)	$ (0.47)	$ (0.78)
Diluted (in dollars per share)	$ (0.16)	$ (0.18)	$ (0.47)	$ (0.78)
Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)	1		1

Earnings (Loss) Per Common Sh_4

Earnings (Loss) Per Common Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	9,862	11,408	9,861	17,635
Exchangeable Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	766	2,654	1,251	8,846
Restricted stock units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	1,197	577	923	557
Stock options and performance-based stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	2,698	2,976	2,486	3,031
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	5,201	5,201	5,201	5,201

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 4,047,000	$ 5,708,000	$ 12,560,000	$ 16,172,000
Share-based compensation expense capitalized as software development costs	0	0	0	0
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	376,000	401,000	1,130,000	1,143,000
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,671,000	5,307,000	11,430,000	15,029,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	2,139,000	4,291,000	7,009,000	12,452,000
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	113,000	113,000	334,000	335,000
RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 1,795,000	$ 1,304,000	$ 5,217,000	$ 3,385,000

Stock-based Compensation - Awar

Stock-based Compensation - Awards Granted (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards granted (in shares)	3,444	84,249	1,053,660	961,313
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards granted (in shares)	18,453	37,361	856,501	461,494

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Tax Contingency [Line Items]
Income tax expense (benefit) (less than $0.1 million for nine months ended September 30, 2018)	$ 135	$ (1,714)	$ 29	$ (2,009)
Effective tax rate	(0.90%)	11.60%	(0.10%)	3.50%
Unrecognized tax benefits					$ 800
Tax receivables agreement, percent of tax savings to be paid	85.00%		85.00%
Evolent Health LLC
Income Tax Contingency [Line Items]
Decrease in deferred tax liabilities				$ 13,100
Evolent Health LLC | Income Tax Expense Benefit
Income Tax Contingency [Line Items]
Decrease in deferred tax liabilities				300
Evolent Health LLC | Additional Paid-in Capital
Income Tax Contingency [Line Items]
Decrease in deferred tax liabilities			$ 900	$ 12,800

Investments In and Advances t_2

Investments In and Advances to Equity Method Investees (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]
Loss from affiliates	$ 1,381	$ 369	$ 2,787	$ 1,446
Equity Method Investee | Services Agreements
Schedule of Equity Method Investments [Line Items]
Revenue related to long-term services agreement (less than $0.1 million - 3 months ended September 30, 2017)	$ 5,100	$ 100	$ 5,900	$ 400
Minimum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	4.00%		4.00%		26.00%
Equity method investment, ownership percentage					27.00%
Maximum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	40.00%		40.00%		40.00%
Equity method investment, ownership percentage					40.00%

Non-controlling Interests (Deta

Non-controlling Interests (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended					3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2018	Aug. 31, 2017	Jun. 30, 2017	May 31, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Aug. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jul. 31, 2017	Apr. 30, 2017	Feb. 28, 2017	Jun. 05, 2015
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests as of beginning-of-period									$ 35,427
Reclassification of non-controlling interests									0		$ 0
Net income (loss) attributable to non-controlling interests						$ (126)	$ (541)		(680)	$ (8,471)
Non-controlling interests as of end-of-period						10,008			10,008		35,427
Non-controlling Interests
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests as of beginning-of-period						10,148	34,680		35,427	209,588	209,588
Cumulative-effect adjustment from adoption of new accounting principle						0	0		594	0
Decrease in non-controlling interests as a result of Class B Exchanges						0	0		(25,334)	(168,883)
Reclassification of non-controlling interests						(14)	1,793		1	3,698	3,824
Net income (loss) attributable to non-controlling interests							(541)		(680)	(8,471)
Non-controlling interests as of end-of-period			$ 34,680			$ 10,008	$ 35,932		$ 10,008	$ 35,932	$ 35,427
Class A
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)											20,100
Proceeds from issuance of common stock, net of payments of stock issuance costs		$ 166,900
Class A | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)	3,000	8,800	4,500	7,000	7,500			19,700			8,816
Class A | Investor Stockholders
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)											12,600
Class A | Investor Stockholders | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)	1,800		3,800	3,800	4,400
Class A | Management Selling Stockholders
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)											100
Class A | Management Selling Stockholders | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)				100
Class A | Evolent Health, Selling Stockholders
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)											7,400
Class A | Evolent Health, Selling Stockholders | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)	1,200		700	3,100	3,100
Evolent Health LLC
Noncontrolling Interest [Line Items]
Parent's ownership percentage	98.90%	96.60%	96.10%	90.50%	83.90%	99.00%		96.60%	99.00%		96.60%	96.10%	84.90%	77.40%	70.30%

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Liabilities
Contingent consideration, fair value	$ 8,300	$ 8,600	$ 8,300	$ 8,600	$ 8,200	$ 8,700	$ 8,500	$ 8,300
Realized and unrealized (gains) losses, net	100	$ 100	(400)	$ 300
Recurring
Assets
Cash and cash equivalents	41,186		41,186			60,535
Restricted cash and restricted investments	32,028		32,028			16,575
Total	73,214		73,214			77,110
Liabilities
Contingent consideration	8,300		8,300			8,700
Recurring | Level 1
Assets
Cash and cash equivalents	41,186		41,186			60,535
Restricted cash and restricted investments	32,028		32,028			16,575
Total	73,214		73,214			77,110
Liabilities
Contingent consideration	0		0			0
Recurring | Level 2
Assets
Cash and cash equivalents	0		0			0
Restricted cash and restricted investments	0		0			0
Total	0		0			0
Liabilities
Contingent consideration	0		0			0
Recurring | Level 3
Assets
Cash and cash equivalents	0		0			0
Restricted cash and restricted investments	0		0			0
Total	0		0			0
Liabilities
Contingent consideration	$ 8,300		$ 8,300			$ 8,700

Fair Value Measurement - Change

Fair Value Measurement - Changes in Contingent Consideration (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of beginning of period	$ 8,200	$ 8,500	$ 8,700	$ 8,300
Realized and unrealized (gains) losses, net	100	100	(400)	300
Balance as of end of period	$ 8,300	$ 8,600	$ 8,300	$ 8,600

Fair Value Measurement - Valuat

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Fair Value	$ 8,300	$ 8,700	$ 8,200	$ 8,600	$ 8,500	$ 8,300
Level 3 | Real options approach | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Fair Value	$ 8,300	$ 8,700
Level 3 | Real options approach | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	1.127	0.925
Level 3 | Real options approach | Discount rate/time value | Contingent consideration | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.038	0.027
Level 3 | Real options approach | Discount rate/time value | Contingent consideration | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.045	0.040
Level 3 | Real options approach 2017-2021 | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, period	5 years	5 years
Level 3 | Real options approach 2017-2021 | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Theoretical recurring revenue	$ 1,000	$ 1,000
Level 3 | Real options approach 2019-2021 | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.786
Level 3 | Real options approach 2019-2021 | Risk-adjusted recurring revenue CAGR | Contingent consideration | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges		0.192

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Equity Method Investee | Services Agreements
Related Party Transaction [Line Items]
Revenue related to long-term services agreement (less than $0.1 million - 3 months ended September 30, 2017)	$ 5.1	$ 0.1	$ 5.9	$ 0.4

Related Parties Related Parties

Related Parties Related Parties - Revenues and Expenses (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue
Revenues		$ 149,947	$ 107,912	$ 433,959	$ 321,221
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)	[1]	73,967	68,281	214,945	203,804
Selling, general and administrative expenses	[1]	59,566	45,834	172,495	150,474
Affiliates
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)		2,390	5,299	6,842	17,382
Selling, general and administrative expenses		241	514	620	1,038
Transformation services
Revenue
Revenues	[1]	9,230	8,204	23,950	23,799
Transformation services | Affiliates
Revenue
Revenues		5,332	352	6,112	597
Platform and operations services
Revenue
Revenues	[1]	118,094	99,708	341,258	297,422
Platform and operations services | Affiliates
Revenue
Revenues		$ 12,180	$ 9,411	$ 27,072	$ 24,764
[1]	See Note 16 for amounts related to affiliates included in these line items.

Segment Reporting (Details)

Segment Reporting (Details)		3 Months Ended		9 Months Ended
		Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segment	Sep. 30, 2017USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment				2
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ 149,947,000	$ 107,912,000	$ 433,959,000	$ 321,221,000
Adjusted EBITDA		4,797,000	2,648,000	17,595,000	(5,689,000)
Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		130,861,000	107,912,000	376,157,000	321,221,000
Adjusted EBITDA		4,065,000	2,648,000	16,674,000	(5,689,000)
Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		22,829,000	0	69,353,000	0
Adjusted EBITDA		732,000	0	921,000	0
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(3,743,000)	0	(11,551,000)	0
Adjusted EBITDA		4,797,000	2,648,000	17,595,000	(5,689,000)
Transformation services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		9,230,000	8,204,000	27,605,000	23,799,000
Revenues	[1]	9,230,000	8,204,000	23,950,000	23,799,000
Transformation services | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		9,230,000		23,950,000
Transformation services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		9,230,000	8,204,000	27,605,000	23,799,000
Transformation services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		0	0	0	0
Transformation services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		0	0	0	0
Platform and operations services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		118,308,000	100,157,000	342,748,000	298,646,000
Revenues	[1]	118,094,000	99,708,000	341,258,000	297,422,000
Platform and operations services | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		116,226,000		335,509,000
Platform and operations services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		121,845,000	100,157,000	353,697,000	298,646,000
Platform and operations services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		0	0	0	0
Platform and operations services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		(3,537,000)	0	(10,949,000)	0
Premiums
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		22,623,000	0	68,751,000	0
Services Revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		127,538,000	108,361,000	370,353,000	322,445,000
Services Revenue | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		131,075,000	108,361,000	381,302,000	322,445,000
Services Revenue | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		0	0	0	0
Services Revenue | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		(3,537,000)	0	(10,949,000)	0
Balances without adoption of ASC 606
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		150,161,000	108,361,000	439,104,000	322,445,000
Balances without adoption of ASC 606 | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		131,075,000	108,361,000	381,302,000	322,445,000
Balances without adoption of ASC 606 | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		22,829,000	0	69,353,000	0
Balances without adoption of ASC 606 | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		(3,743,000)	0	(11,551,000)	0
Balances without adoption of ASC 606 | Transformation services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		9,556,000		25,272,000
Balances without adoption of ASC 606 | Platform and operations services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		117,942,000		339,485,000
Balances without adoption of ASC 606 | Premiums
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		22,623,000		68,751,000
Balances without adoption of ASC 606 | Premiums | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		0		0
Balances without adoption of ASC 606 | Premiums | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		22,829,000		69,353,000
Balances without adoption of ASC 606 | Premiums | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted Revenue		(206,000)		(602,000)
Adjustments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(214,000)	(449,000)	(647,000)	(1,224,000)
Adjustments | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(214,000)	(449,000)	(647,000)	(1,224,000)
Adjustments | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Adjustments | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0	0
Adjustments | Transformation services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0		0
Adjustments | Premiums | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	$ 0	0	$ 0
Adjustments | Accounting Standards Update 2014-09
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				(4,498,000)
Adjustments | Accounting Standards Update 2014-09 | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				(4,498,000)
Adjustments | Accounting Standards Update 2014-09 | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				0
Adjustments | Accounting Standards Update 2014-09 | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				0
Adjustments | Accounting Standards Update 2014-09 | Transformation services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(326,000)		(1,322,000)
Adjustments | Accounting Standards Update 2014-09 | Transformation services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				3,700,000
Adjustments | Accounting Standards Update 2014-09 | Platform and operations services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ 152,000		1,773,000
Adjustments | Accounting Standards Update 2014-09 | Platform and operations services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues				$ 800,000
[1]	See Note 16 for amounts related to affiliates included in these line items.

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting [Abstract]
Net Income (Loss) Attributable to Evolent Health, Inc.	$ (12,429)	$ (12,588)	$ (35,971)	$ (47,506)
Interest income	968	411	2,918	813
Interest expense	(853)	(880)	(2,561)	(2,781)
(Provision) benefit for income taxes	(135)	1,714	(29)	2,009
Depreciation and amortization expenses	(10,352)	(7,717)	(29,882)	(21,236)
Income (loss) from equity method investees	(1,381)	(369)	(2,787)	(1,446)
Change in fair value of contingent consideration and indemnification asset	(100)	(100)	1,404	(300)
Other income (expense), net	(124)	15	(64)	21
Net income (loss) attributable to non-controlling interests	126	541	680	8,471
ASC 606 transition adjustments	0	0	(4,498)	0
Purchase accounting adjustments	(214)	(449)	(647)	(1,224)
Stock-based compensation expense	(4,047)	(5,708)	(12,560)	(16,172)
Severance costs	0	0	(1,489)	0
Amortization of contract cost assets	(658)	0	(1,797)	0
Transaction costs	(456)	(2,694)	(2,254)	(9,972)
Adjusted EBITDA	$ 4,797	$ 2,648	$ 17,595	$ (5,689)

True Health Claims Reserves (De

True Health Claims Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance			$ 0
Incurred costs related to current period	$ 16,992	$ 0	52,169	$ 0
Paid costs related to current period			41,831
Change during the period			10,338
Ending balance	$ 10,338		$ 10,338

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Accrued property and equipment purchases	$ 501	$ 83
Increase to goodwill from measurement period adjustments related to business combinations	4	1,766
Decrease in accrued financing costs related to 2021 Notes	0	196
Consideration for asset acquisitions or business combinations	500	0
Settlement of escrow related to asset acquisition	2,519	0
Settlement of indemnification asset	1,004	0
Tax benefit related to Accordion intangible technology	0	2,042
Effects of Class B Exchanges
Decrease in deferred tax liability as a result of securities offerings	25,334	168,883
Decrease in deferred tax liability as a result of securities offerings	$ 908	$ 12,992

Subsequent Events - Acquisition

Subsequent Events - Acquisition of New Century Health (Details) - USD ($)	Oct. 01, 2018	Sep. 30, 2018	Sep. 30, 2017
Subsequent Event [Line Items]
Cash		$ 11,552,000	$ 3,694,000
New Century Health | Subsequent Event
Subsequent Event [Line Items]
Consideration transferred	$ 221,600,000
Cash	$ 117,200,000
Consideration transferred, shares issued, percentage of total shares issued and outstanding	3.80%
Contingent liability, earn-out potential	$ 20,000,000
Consideration transferred, shares issuable, contingent liability, maximum (in shares)	1,000,000
New Century Health | Subsequent Event | Class B
Subsequent Event [Line Items]
Consideration transferred, shares issued (in shares)	3,100,000
New Century Health | Subsequent Event | Common Class B Units
Subsequent Event [Line Items]
Consideration transferred, shares issued (in shares)	3,100,000

Subsequent Events - Convertible

Subsequent Events - Convertible Debt Issuance (Details) - Senior Convertible Notes due 2025 - Senior Notes - Subsequent Event $ / shares in Units, shares in Millions	1 Months Ended
	Oct. 31, 2018USD ($)shares$ / shares	Oct. 24, 2018USD ($)	Oct. 22, 2018USD ($)
Subsequent Event [Line Items]
Face amount	$ 172,500,000	$ 22,500,000	$ 150,000,000
Interest rate	1.50%
Proceeds from issuance of debt	$ 167,300,000
Debt issuance costs	5,200,000
Debt conversion denominator shares per principal amount	$ 1,000
Conversion price (in dollars per share) | $ / shares	$ 33.43
Initial conversion amount (in shares) | shares	5.2
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Repurchase covenant, sale price as a percentage of conversion price	130.00%
Repurchase covenant, trading days (at least)	20 days
Repurchase covenant, consecutive trading days	30 days
Repurchase covenant, price due to change in sale price as percentage of conversion price	100.00%
Common Stock | Class A
Subsequent Event [Line Items]
Initial conversion rate per $1000 principal amount	0.0299135